1
|
Pozuelo Moyano B, Orgeta V, von Gunten A, Vandel P, Ma R, Stewart R, Mueller C. Treatment-resistant late-life depression prevalence and clinical/sociodemographic correlates: An electronic health records study. J Affect Disord 2025; 381:77-83. [PMID: 40174785 DOI: 10.1016/j.jad.2025.03.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Revised: 03/24/2025] [Accepted: 03/29/2025] [Indexed: 04/04/2025]
Abstract
BACKGROUND Treatment-resistant late-life depression (TRLLD) remains a clinical challenge. Our aim was to identify demographic and clinical factors associated with TRLLD. METHODS A large naturalistic retrospective cohort study was conducted using mental health records from south London. Patients were selected at first recorded depression diagnosis after the age of 60. We defined TRLLD when ≥3 antidepressants were prescribed across their mental health record or a natural language processing algorithm indicated depression was described as treatment-resistant. We collected demographic and clinical characteristics around the first depressive episode diagnosis at age ≥ 60 and used multivariate logistic regression models to investigate factors associated with TRLLD. RESULTS Of 8171 patients with late-life depression, 1443 (17.7 %) had TRLLD. Amongst those with severe, psychotic or recurrent depression the prevalence of TRLLD was 30.7 %, 31.4 % and 27.0 % respectively. Female sex, recurrent, severe, or psychotic depression and higher self-harm risk were associated with higher odds of TRLLD after adjustment for demographics (Adjusted Odds ratio (aOR): 1.36, 2.05, 2.34, 2.21 and 1.30 respectively). Older age, Black ethnicity, cognitive impairment and difficulties in activities of daily living were associated with a lower likelihood of TRLLD (aOR: 0.97, 0.65, 0.71 and 0.76 respectively). Several physical conditions examined were associated with increased odds for TRLLD, the strongest association was with hypertension (aOR: 2.20). CONCLUSIONS This is the first large-scale study examining the socio-demographic data as well as psychiatric and physical comorbidities in TRLLD without known dementia. Prevention and management of multi-morbidity should be considered in primary or secondary prevention of treatment-resistant depression.
Collapse
Affiliation(s)
- Beatriz Pozuelo Moyano
- Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital (CHUV) and University of Lausanne, Prilly, Switzerland.
| | - Vasiliki Orgeta
- Division of Psychiatry, University College London, London, UK
| | - Armin von Gunten
- Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital (CHUV) and University of Lausanne, Prilly, Switzerland
| | - Pierre Vandel
- Service of Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital (CHUV) and University of Lausanne, Prilly, Switzerland
| | - Ruimin Ma
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK
| | - Robert Stewart
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK; South London and Maudsley NHS Foundation Trust, London, UK
| | - Christoph Mueller
- King's College London, Institute of Psychiatry, Psychology and Neuroscience, London, UK; South London and Maudsley NHS Foundation Trust, London, UK
| |
Collapse
|
2
|
Han W, Su Y, Wang X, Yang T, Zhao G, Mao R, Zhu N, Zhou R, Wang X, Wang Y, Peng D, Wang Z, Fang Y, Chen J, Sun P. Altered resting-state brain activity in patients with major depression disorder and bipolar disorder: A regional homogeneity analysis. J Affect Disord 2025; 379:313-322. [PMID: 40081596 DOI: 10.1016/j.jad.2025.03.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Revised: 03/04/2025] [Accepted: 03/10/2025] [Indexed: 03/16/2025]
Abstract
BACKGROUND Major Depressive Disorder (MDD) and Bipolar Disorder (BD) exhibit overlapping depressive symptoms, complicating their differentiation in clinical practice. Traditional neuroimaging studies have focused on specific regions of interest, but few have employed whole-brain analyses like regional homogeneity (ReHo). This study aims to differentiate MDD from BD by identifying key brain regions with abnormal ReHo and using advanced machine learning techniques to improve diagnostic accuracy. METHODS A total of 63 BD patients, 65 MDD patients, and 70 healthy controls were recruited from the Shanghai Mental Health Center. Resting-state functional MRI (rs-fMRI) was used to analyze ReHo across the brain. We applied Support Vector Machine (SVM) and SVM-Recursive Feature Elimination (SVM-RFE), a robust machine learning model known for its high precision in feature selection and classification, to identify critical brain regions that could serve as biomarkers for distinguishing BD from MDD. SVM-RFE allows for the recursive removal of non-informative features, enhancing the model's ability to accurately classify patients. Correlations between ReHo values and clinical scores were also evaluated. RESULTS ReHo analysis revealed significant differences in several brain regions. The study results revealed that, compared to healthy controls, both BD and MDD patients exhibited reduced ReHo in the superior parietal gyrus. Additionally, MDD patients showed decreased ReHo values in the Right Lenticular nucleus, putamen (PUT.R), Right Angular gyrus (ANG.R), and Left Superior occipital gyrus (SOG.L). Compared to the MDD group, BD patients exhibited increased ReHo values in the Left Inferior occipital gyrus (IOG.L). In BD patients only, the reduction in ReHo values in the right superior parietal gyrus and the right angular gyrus was positively correlated with Hamilton Depression Scale (HAMD) scores. SVM-RFE identified the IOG.L, SOG.L, and PUT.R as the most critical features, achieving an area under the curve (AUC) of 0.872, with high sensitivity and specificity in distinguishing BD from MDD. CONCLUSION This study demonstrates that BD and MDD patients exhibit distinct patterns of regional brain activity, particularly in the occipital and parietal regions. The combination of ReHo analysis and SVM-RFE provides a powerful approach for identifying potential biomarkers, with the left inferior occipital gyrus, left superior occipital gyrus, and right putamen emerging as key differentiating regions. These findings offer valuable insights for improving the diagnostic accuracy between BD and MDD, contributing to more targeted treatment strategies.
Collapse
Affiliation(s)
- Weijian Han
- Qingdao Mental Health Center, Qingdao 266034, Shandong, China
| | - Yousong Su
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China
| | - Xiangwen Wang
- Qingdao Mental Health Center, Qingdao 266034, Shandong, China
| | - Tao Yang
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China
| | - Guoqing Zhao
- Department of Psychology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
| | - Ruizhi Mao
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China
| | - Na Zhu
- Shanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai, China
| | - Rubai Zhou
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China
| | - Xing Wang
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China
| | - Yun Wang
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China
| | - Daihui Peng
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China
| | - Zuowei Wang
- Division of Mood Disorders, Shanghai Hongkou Mental Health Center, Shanghai 200083, China; Clinical Research Center for Mental Health, School of Medicine, Shanghai University, Shanghai 200083, China
| | - Yiru Fang
- Department of Psychiatry & Affective Disorders Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Clinical Research Center, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China; State Key Laboratory of Neuroscience, Shanghai Institue for Biological Sciences, CAS, Shanghai 200031, China; Shanghai Key Laboratory of Psychotic Disorders, Shanghai 201108, China
| | - Jun Chen
- Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, 600 South Wan Ping Road, Shanghai 200030, China.
| | - Ping Sun
- Qingdao Mental Health Center, Qingdao 266034, Shandong, China.
| |
Collapse
|
3
|
Ou A, Wu GWY, Kassel MT, Mackin RS, Rampersaud R, Reus VI, Mellon SH, Wolkowitz OM. Cognitive function in physically healthy, unmedicated individuals with major depression: Relationship with depressive symptoms and antidepressant response. J Affect Disord 2025; 378:191-200. [PMID: 40032138 DOI: 10.1016/j.jad.2025.02.115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/08/2024] [Revised: 01/31/2025] [Accepted: 02/27/2025] [Indexed: 03/05/2025]
Abstract
We studied cognitive dysfunction in Major Depressive Disorder (MDD) in a sample of healthy, unmedicated individuals without comorbidities. Additionally, we studied the association of cognitive function with response to selective serotonin reuptake inhibitors (SSRIs). Our sample consisted of 113 adult MDD participants and 88 matched healthy controls (HC). Sixty-nine of the MDD participants completed 8 weeks of SSRI treatment. All participants completed a cognitive battery assessing processing speed, executive function, and learning and memory at baseline. This was repeated at week 8 for MDD participants. MDD "Responders" were defined as having ≥50 % improvement on the Hamilton Depression Rating Scale score at week 8 compared to baseline. At baseline, MDD participants performed significantly worse than HC participants on the Symbol Digit Modalities Test (SDMT) (p < .001), Stroop color naming (p = .005) and color-word naming (p = .047), and Brief Visuospatial Memory Test-Revised (BVMT) total recall (p = .02), delayed recall (p < .001), and percent retention (p = .01). MDD participants improved significantly on 6 of the cognitive assessments over 8 weeks. However, there were no significant baseline differences between Responders and Non-responders. SSRI Response was associated with improvement only in the HVLT total recall (p = .02). Our results suggest: 1) a differentiated pattern of cognitive dysfunction exists in healthy, unmedicated MDD compared to HCs; 2) baseline cognition does not delineate an SSRI-responsive/-nonresponsive subgroup, and 3) SSRI response is not associated with broad cognitive improvement after 8 weeks when compared to Non-responders, emphasizing unmet therapeutic challenges.
Collapse
Affiliation(s)
- Anna Ou
- Weill Institute for Neurosciences and Department of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; University of California San Diego (UCSD) School of Medicine, La Jolla, CA, USA
| | - Gwyneth W Y Wu
- Weill Institute for Neurosciences and Department of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA.
| | - Michelle T Kassel
- Weill Institute for Neurosciences and Department of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA
| | - R Scott Mackin
- Weill Institute for Neurosciences and Department of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA
| | - Ryan Rampersaud
- Weill Institute for Neurosciences and Department of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
| | - Victor I Reus
- Weill Institute for Neurosciences and Department of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
| | - Synthia H Mellon
- Department of OB-GYN and Reproductive Sciences, UCSF School of Medicine, San Francisco, CA, USA
| | - Owen M Wolkowitz
- Weill Institute for Neurosciences and Department of Psychiatry and Behavioral Sciences, University of California San Francisco (UCSF) School of Medicine, San Francisco, CA, USA
| |
Collapse
|
4
|
Velásquez Cabrera DM, De la Roca-Chiapas JM, Hernández-González MA, Reyes Pérez V, Villada C. Correlation Between COVID-19 Recovery, Executive Function Decline, and Emotional State. Psychol Res Behav Manag 2025; 18:1007-1019. [PMID: 40292029 PMCID: PMC12034288 DOI: 10.2147/prbm.s487382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2024] [Accepted: 04/08/2025] [Indexed: 04/30/2025] Open
Abstract
Objective The aim of this study was to determine whether there is a relationship between the time since recovery from coronavirus disease 2019 (COVID-19) and alterations in executive functions. We also evaluate the emotional state of post-COVID-19 patients. Patients and Methods We assessed patients between 18 and 50 years old, who had a history of COVID-19 with mild, moderate, or severe illness. We used the Batería Neuropsicológica de Funciones Ejecutivas y Lóbulos Frontales-3 (BANFE-3), Mini-Mental State Examination (MMSE), and Mini-International Neuropsychiatric Interview (MINI), in addition to a semi-structured interview. Spearman's correlation coefficient was used, with a p value <0.05 indicating significance. Results We evaluated 67 patients with a mean age of 34.6±9.6 years, most of whom had ≥13 years of schooling (n=55, 82.1%). Among them, 52 (77.6%) reported persistent symptoms after resolution of the condition, with fatigue being the most frequent (n=20, 29.9%). Most participants had an adequate score on the MMSE (n=60, 89.6%). However, 19 (28.4%) showed alterations in the BANFE-3 total score, with mental flexibility as the most affected function (n=25, 37.3%). In participants from the first COVID-19 wave, a negative correlation was observed between the standardized orbitofrontal area scores and the time since recovery from the infection (r=-0.841, p=0.016), suggesting a pattern of deterioration over time, mainly in stimulus inhibition (r=0.880, p=0.021). Regarding emotional state, 45 subjects (67.2%) exhibited emotional alterations, with anxiety symptoms being the most frequent (n=33, 49.3%). Furthermore, individuals with depressive symptoms (n=32, 47.8%) were more likely to experience executive function impairment after COVID-19 (ExpB 0.302, 95% CI 0.098-0.933, p=0.038). Conclusion COVID-19 could lead to alterations in executive functions, probably resulting from progressive damage to orbitofrontal area functions, mainly in stimulus inhibition. However, the generalizability of these findings is limited, highlighting the need for further research with robust methodology. Furthermore, depression appears to be an indicator of cognitive impairment in individuals recovering from COVID-19. Therefore, cognitive rehabilitation and psychological support are essential for patients affected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection.
Collapse
Affiliation(s)
| | | | | | | | - Carolina Villada
- Department of Psychology, University of Guanajuato, Guanajuato, Mexico
| |
Collapse
|
5
|
Piccirillo ML, Graupensperger S, Walukevich-Dienst K, Lehinger E, Smith-LeCavalier KN, Foster KT, Larimer ME. Examining the longer-term efficacy of brief, alcohol-focused personalized feedback interventions for individuals with internalizing distress: Secondary analysis of a randomized controlled trial. Addiction 2025. [PMID: 40202024 DOI: 10.1111/add.70044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2024] [Accepted: 02/19/2025] [Indexed: 04/10/2025]
Abstract
BACKGROUND AND AIMS Efficacy of brief alcohol interventions for young adults with internalizing distress (i.e. symptoms of depression, anxiety and stress) is unclear. We tested the moderating effect of internalizing distress on the efficacy of alcohol single- and multicomponent personalized feedback interventions (PFIs). DESIGN Secondary data were analyzed from a randomized controlled trial (RCT) testing the efficacy of single and multicomponent PFIs, compared with an attention-only control condition. SETTING Participants were sampled from two West Coast universities in the United States. All study protocols were completed online. PARTICIPANTS Participants (n = 1137) were college students (63% female; Mage = 20.1 years; 62.6% non-Hispanic white) who reported on internalizing distress at baseline. Some individuals reported clinically significant symptoms (depression: mild/moderate = 24.0%, severe/extremely severe = 10.5%; anxiety: mild/moderate = 19.6%, severe/extremely severe = 11.4%; and stress: mild/moderate = 37.5%, severe/extremely severe = 6.0%). INTERVENTIONS There were four different alcohol single-component PFIs administered and an attention-only PFI control. Alcohol PFIs varied in their complexity and single-component PFIs (i.e. personalized normative feedback) were compared with multicomponent PFI (i.e. containing additional alcohol-focused psychoeducation). MEASUREMENTS Baseline levels of internalizing distress were measured using the summed total of the Depression, Anxiety and Stress Scales (DASS). Drinking outcomes (alcohol consumption, peak eBAC, alcohol-related consequences) were measured at baseline, 3, 6 and 12 months post-intervention. FINDINGS Alcohol PFI (compared with attention-only control) reduced alcohol consumption and related consequences at 6-month [rate ratio (RR)Consumption = 0.85, P = 0.004] or 12-month follow-ups (RRConsumption = 0.76, P < 0.001; RRConsequences = 0.85, P = 0.020), regardless of baseline DASS score. Participants with higher DASS scores (compared with those with lower DASS scores) reported lower 6-month alcohol consumption after receiving a single-component intervention (RR = 0.80, P < 0.001). However, individuals with higher DASS scores (compared to those with lower DASS scores) reported more 6-month alcohol-related consequences after receiving a multicomponent intervention (RR = 0.78, P = 0.004). CONCLUSIONS Personalized feedback interventions may demonstrate efficacy towards reducing drinking in young adults and appear similarly beneficial across levels of internalizing distress, although lower-complexity interventions may be more efficacious.
Collapse
Affiliation(s)
- Marilyn L Piccirillo
- Department of Psychology, University of Washington, Seattle, WA, USA
- Department of Psychiatry, Division of Addiction Psychiatry, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ, USA
| | - Scott Graupensperger
- Center for the Study of Health and Risk Behaviors, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
| | - Katherine Walukevich-Dienst
- Center for the Study of Health and Risk Behaviors, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
| | - Elizabeth Lehinger
- Center for the Study of Health and Risk Behaviors, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
| | | | - Katherine T Foster
- Department of Psychology, University of Washington, Seattle, WA, USA
- Department of Global Health, University of Washington, Seattle, WA, USA
| | - Mary E Larimer
- Department of Psychology, University of Washington, Seattle, WA, USA
- Center for the Study of Health and Risk Behaviors, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
| |
Collapse
|
6
|
Cau Q, Gandré C, Lengagne P. Recurrent major depression, employment and transitions to unemployment and disability benefits. Soc Sci Med 2025; 377:118056. [PMID: 40311499 DOI: 10.1016/j.socscimed.2025.118056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2025] [Revised: 03/27/2025] [Accepted: 04/07/2025] [Indexed: 05/03/2025]
Abstract
This study assesses the effects of recurrent major depression on employment and transitions to unemployment and disability benefits. Examining this issue is essential for designing timely interventions aimed to sustain individuals' employment. We rely on register data of a sample of individuals initially employed-a 2% sample of employees representative of French private-sector employees-followed up to eight years before and eight years after the year of diagnosis, aged between 20 and 60 years, over the period 2000-2015. We estimate that recurrent major depression persistently decreases the likelihood of being employed by 35 percentage points and annual earnings by 51%, and leads to increase the probability of long absence by 47 percentage points and the probability of permanent disability benefit recipiency by 33 percentage points. The effect sizes are similar between men and women. We find differences between age groups. For young and middle-aged individuals, recurrent major depression implies a decrease in employment rates, an increase in unemployment benefit rates and a persistent increase in disability benefit recipiency rates. Many young ill individuals remain attached to the labor market but experience unemployment and a large decline in annual earnings. For older individuals, recurrent major depression leads to a larger decrease in employment rates and a greater increase in disability benefit recipiency rates, compared to younger individuals. We conclude that differentiated policies tailored to age groups might be developed to support the employment of individuals with recurrent major depression.
Collapse
Affiliation(s)
- Quentin Cau
- Institute for Research and Information in Health Economics (IRDES, Paris, France), 21 23 Rue des Ardennes, 75019, Paris, France
| | - Coralie Gandré
- Institute for Research and Information in Health Economics (IRDES, Paris, France), 21 23 Rue des Ardennes, 75019, Paris, France
| | - Pascale Lengagne
- Institute for Research and Information in Health Economics (IRDES, Paris, France), 21 23 Rue des Ardennes, 75019, Paris, France.
| |
Collapse
|
7
|
Teixeira AL, Gregg A, Gentry MT, Gujral S, Rapp E, Oberlin L, Ajilore O, Weisenbach S, Patrick R. Cognitive Deficits in Late-Life Depression: From Symptoms and Assessment to Therapeutics. FOCUS (AMERICAN PSYCHIATRIC PUBLISHING) 2025; 23:183-194. [PMID: 40235602 PMCID: PMC11995896 DOI: 10.1176/appi.focus.20240046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/17/2025]
Abstract
Cognitive symptoms and deficits are core features of late-life depression (LLD), with an estimated 20%-50% of affected individuals meeting diagnostic criteria for mild cognitive impairment (MCI). Cognitive deficits, especially executive dysfunction, have consistently been associated with poorer treatment outcomes among people with LLD. Furthermore, distinguishing depression with cognitive complaints or cognitive impairment from the early stages of Alzheimer's disease (AD) can be challenging. Cognitive concerns are often emphasized among those with LLD, although, paradoxically, their description of memory difficulty may include detailed recall of specific memory lapses. Conversely, people with AD often have limited insight into their progressive cognitive decline, minimizing and concealing their cognitive difficulties. Neuropsychological assessment is one of the most useful means of clarifying this differential diagnosis. A subcortical cognitive pattern is commonly observed among people with LLD, including psychomotor slowing, variable attention, and executive dysfunction, which can affect memory encoding and free recall. A broad range of therapeutic approaches have been applied to older adults experiencing LLD along with cognitive symptoms, MCI, or dementia. Most studies focus on treatments to address LLD or MCI, with relatively fewer examining treatments specifically at this intersection. Nonpharmacological strategies, including aerobic exercise, cognitive remediation, and neuromodulation, are highly recommended to improve both depression and cognition. Antidepressants may have benefits for elements of cognition among people with LLD, but they have less evidence for their efficacy for people with cognitive deficits and dementia. This review provides an updated conceptual and practical framework for clinicians evaluating and treating LLD.
Collapse
Affiliation(s)
- Antonio L Teixeira
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Allison Gregg
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Melanie T Gentry
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Swathi Gujral
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Ellie Rapp
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Lauren Oberlin
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Olusola Ajilore
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Sara Weisenbach
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| | - Regan Patrick
- Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Science Center, San Antonio (Teixeira); McLean Hospital, Harvard Medical School, Belmont, Massachusetts (Gregg, Weisenbach, Patrick); Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota (Gentry); Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh (Rapp, Gujral); Department of Neuroscience, AdventHealth Research Institute, Orlando, Florida, and Weill Cornell Institute of Geriatric Psychiatry, Weill Cornell Medicine, White Plains, New York (Oberlin); Department of Psychiatry, University of Illinois Chicago, Chicago (Ajilore)
| |
Collapse
|
8
|
Lyall LM, Stolicyn A, Lyall DM, Zhu X, Sangha N, Ward J, Strawbridge RJ, Cullen B, Smith DJ. Lifetime depression, sleep disruption and brain structure in the UK Biobank cohort. J Affect Disord 2025; 374:247-257. [PMID: 39719181 DOI: 10.1016/j.jad.2024.12.069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2024] [Revised: 12/17/2024] [Accepted: 12/18/2024] [Indexed: 12/26/2024]
Abstract
Whether depression and poor sleep interact or have statistically independent associations with brain structure and its change over time is not known. Within a subset of UK Biobank participants with neuroimaging and subjective and/or objective sleep data (n = 28,351), we examined associations between lifetime depression and sleep disruption, and their interaction with structural neuroimaging measures, both cross-sectionally and longitudinally. Sleep variables were: self-reported insomnia and difficulty getting up; actigraphy-derived short sleep (<7 h); sustained inactivity bouts during daytime (SIBD); and sleep efficiency. Imaging measures were white matter microstructure, subcortical volumes, cortical thickness and surface area of 24 cortical regions of interest. Individuals with lifetime depression (self-reported, mental health questionnaire or health records) were contrasted with healthy controls. Interactions between depression and difficulty getting up for i) right nucleus accumbens volume and ii) mean diffusivity of forceps minor, reflected a larger negative association of poor sleep in the presence vs. absence of depression. Depression was associated with widespread reductions in white matter integrity. Depression, higher SIBD and difficulty getting up were individually associated with smaller cortical volumes and surface area, particularly in the frontal and parietal lobes. Many regions showed age-related decline, but this was not exacerbated by either depression or sleep disturbance. Overall, we identified widespread cross-sectional associations of both lifetime depression and sleep measures with brain structure. Findings were more consistent with additive rather than synergistic effects - although in some regions we observed greater magnitude of deleterious associations from poor sleep phenotypes in the presence of depression.
Collapse
Affiliation(s)
- Laura M Lyall
- School of Health and Wellbeing, University of Glasgow, Glasgow, UK; Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
| | - Aleks Stolicyn
- Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Donald M Lyall
- School of Health and Wellbeing, University of Glasgow, Glasgow, UK; Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Xingxing Zhu
- School of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Natasha Sangha
- School of Health and Wellbeing, University of Glasgow, Glasgow, UK; Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Joey Ward
- School of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Rona J Strawbridge
- School of Health and Wellbeing, University of Glasgow, Glasgow, UK; Health Data Research, Glasgow, UK; Cardiovascular Medicine Unit, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden
| | - Breda Cullen
- School of Health and Wellbeing, University of Glasgow, Glasgow, UK
| | - Daniel J Smith
- Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| |
Collapse
|
9
|
The NNDC Road Map for Depression Care and Focused Areas of Research. FOCUS (AMERICAN PSYCHIATRIC PUBLISHING) 2025; 23:217-218. [PMID: 40235609 PMCID: PMC11995906 DOI: 10.1176/appi.focus.25023008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/17/2025]
|
10
|
Ercan Dogan A, Aslan Genc H, Balaç S, Hun Senol S, Ayas G, Dogan Z, Bora E, Ceylan D, Şar V. DMN network and neurocognitive changes associated with dissociative symptoms in major depressive disorder: a research protocol. Front Psychiatry 2025; 16:1516920. [PMID: 40236494 PMCID: PMC11996865 DOI: 10.3389/fpsyt.2025.1516920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2024] [Accepted: 02/26/2025] [Indexed: 04/17/2025] Open
Abstract
Introduction Depression is a heterogeneous disorder with diverse clinical presentations and etiological underpinnings, necessitating the identification of distinct subtypes to enhance targeted interventions. Dissociative symptoms, commonly observed in major depressive disorder (MDD) and linked to early life trauma, may represent a unique clinical dimension associated with specific neurocognitive deficits. Although emerging research has begun to explore the role of dissociation in depression, most studies have provided only descriptive analyses, leaving the mechanistic interplay between these phenomena underexplored. The primary objective of this study is to determine whether MDD patients with prominent dissociative symptoms differ from those without such symptoms in clinical presentation, neurocognitive performance, and markers of functional connectivity. This investigation will be the first to integrate comprehensive clinical evaluations, advanced neurocognitive testing, and high-resolution brain imaging to delineate the contribution of dissociative symptoms in MDD. Methods We will recruit fifty participants for each of three groups: (1) depressive patients with dissociative symptoms, (2) depressive patients without dissociative symptoms, and (3) healthy controls. Diagnostic assessments will be performed using the Structured Clinical Interview for DSM-5 (SCID) alongside standardized scales for depression severity, dissociation, and childhood trauma. Neurocognitive performance will be evaluated through a battery of tests assessing memory, attention, executive function, and processing speed. Structural and functional magnetic resonance imaging (MRI) will be conducted on a 3 Tesla scanner, focusing on the connectivity of the Default Mode Network with key regions such as the orbitofrontal cortex, insula, and posterior cingulate cortex. Data analyses will employ SPM-12 and Matlab-based CONN and PRONTO tools, with multiclass Gaussian process classification applied to differentiate the three groups based on clinical, cognitive, and imaging data. Discussion The results of this study will introduce a novel perspective on understanding the connection between major depressive disorder and dissociation. It could also aid in pinpointing a distinct form of depression associated with dissociative symptoms and early childhood stressors. Conclusion Future research, aiming to forecast the response to biological and psychological interventions for depression, anticipates this subtype and provides insights.
Collapse
Affiliation(s)
- Asli Ercan Dogan
- Department of Psychiatry, School of Medicine, Koç University, Istanbul, Türkiye
| | - Herdem Aslan Genc
- Department of Child and Adolescent Psychiatry, School of Medicine, Koç University, Istanbul, Türkiye
- Graduate School of Health Sciences, Koç University, Istanbul, Türkiye
| | - Sinem Balaç
- Graduate School of Health Sciences, Koç University, Istanbul, Türkiye
- Koç University Research Center for Translational Medicine (KUTTAM), Affective Laboratory, Istanbul, Türkiye
| | - Sevin Hun Senol
- Department of Psychiatry, School of Medicine, Koç University, Istanbul, Türkiye
| | - Görkem Ayas
- Graduate School of Health Sciences, Koç University, Istanbul, Türkiye
| | - Zafer Dogan
- Department of EEE, MLIP Research Group & KUIS AI Center, Koç, University, Istanbul, Türkiye
| | - Emre Bora
- Department of Neurosciences, Institute of Health Sciences, Dokuz Eylül University, Izmir, Türkiye
- Department of Psychiatry, School of Medicine, Dokuz Eylül University, Izmir, Türkiye
| | - Deniz Ceylan
- Department of Psychiatry, School of Medicine, Koç University, Istanbul, Türkiye
- Graduate School of Health Sciences, Koç University, Istanbul, Türkiye
- Koç University Research Center for Translational Medicine (KUTTAM), Affective Laboratory, Istanbul, Türkiye
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States
| | - Vedat Şar
- Department of Psychiatry, School of Medicine, Koç University, Istanbul, Türkiye
| |
Collapse
|
11
|
Vicent-Gil M, Trujols J, Sagués T, Serra-Blasco M, Navarra-Ventura G, Mantellini CL, Crivillés S, Portella MJ, Cardoner N. Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder. Ann Gen Psychiatry 2025; 24:16. [PMID: 40108685 PMCID: PMC11924669 DOI: 10.1186/s12991-025-00552-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2024] [Accepted: 02/12/2025] [Indexed: 03/22/2025] Open
Abstract
BACKGROUND Desvenlafaxine, a serotonin-norepinephrine reuptake inhibitor, has demonstrated efficacy in improving affective symptoms of Major Depressive Disorder (MDD); however, its effects on associated cognitive and functional difficulties remain underexplored. This study seeks to assess the antidepressant effects of desvenlafaxine in patients with SSRI-resistant MDD, its impact on both objective and subjective cognitive performance, where cognitive improvements occur independently of clinical recovery or not, and its influence on psychosocial functioning. METHODS An observational case-control prospective study with 66 participants was conducted, including 26 patients with a current MDD episode, with an inadequate SSRI response, and with the prescription of desvenlafaxine as the next antidepressant therapeutic option, and 40 healthy controls. Sociodemographic, clinical, cognitive, and functional assessments were conducted both before and after a 12-week treatment period. Changes were analyzed using two tailed paired-samples t-tests, with Cohen's d for effect sizes. Cognitive improvements were compared between the patients who achieved remission and those who did not. RESULTS Patients showed significant improvements in depressive and anxiety symptoms, attention/working memory and processing speed, self-perceived cognitive difficulties and psychosocial functioning. Highlighting the fact these cognitive enhancements occurred independently of patients' clinical improvement. CONCLUSIONS The findings of this study focus on the therapeutic potential of desvenlafaxine, demonstrating its efficacy not only in ameliorating clinical and functional symptoms but also in addressing specific cognitive impairments in patients with depression. Further research is needed to elucidate the mechanisms underlying desvenlafaxine's effects and optimize treatment strategies for individuals with MDD. TRIAL REGISTRATION NUMBER NCT03432221 (clinical. TRIALS gov). Registration date: 08-01-2018.
Collapse
Affiliation(s)
- Muriel Vicent-Gil
- Sant Pau Mental Health, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041, Barcelona, Spain
- Hospital de la Sant Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025, Barcelona, Spain
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - Joan Trujols
- Sant Pau Mental Health, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041, Barcelona, Spain
- Hospital de la Sant Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025, Barcelona, Spain
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - Teresa Sagués
- Mental Health Department, Hospital Universitari Parc Taulí, Sabadell, Spain
| | - Maria Serra-Blasco
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- ICOnnecta't Digital Health Program, Catalan Institute of Oncology, Hospitalet del Llobregat, Spain
- The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet del Llobregat, Spain
| | - Guillem Navarra-Ventura
- Department of Medicine, University of the Balearic Islands, Palma, Mallorca, Spain
- Research Institute of Health Sciences, University of the Balearic Islands, Palma, Mallorca, Spain
- Health Research Institute of the Balearic Islands, Hospital Universitari Son Espases, Palma, Mallorca, Spain
- CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain
| | - Cecilia Lucía Mantellini
- Psychiatry and Psychology Department, Clinical Institute of Neuroscience, Hospital Clínic de Barcelona, Barcelona, Spain
| | - Sara Crivillés
- Sant Pau Mental Health, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041, Barcelona, Spain
- Hospital de la Sant Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025, Barcelona, Spain
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
| | - Maria J Portella
- Sant Pau Mental Health, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041, Barcelona, Spain
- Hospital de la Sant Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025, Barcelona, Spain
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain
| | - Narcís Cardoner
- Sant Pau Mental Health, Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041, Barcelona, Spain.
- Hospital de la Sant Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025, Barcelona, Spain.
- CIBER de Salud Mental, Instituto de Salud Carlos III, Madrid, Spain.
- Department of Psychiatry and Legal Medicine, Universitat Autònoma de Barcelona, 08193, Bellaterra, Spain.
| |
Collapse
|
12
|
Bravi B, Verga C, Palladini M, Poletti S, Buticchi C, Stefania S, Stefano D, Colombo C, Comai S, Benedetti F. Effects of kynurenine pathway metabolites on choroid plexus volume, hemodynamic response, and spontaneous neural activity: A new mechanism for disrupted neurovascular communication and impaired cognition in mood disorders. Brain Behav Immun 2025; 125:414-427. [PMID: 39909168 DOI: 10.1016/j.bbi.2025.01.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2024] [Revised: 01/07/2025] [Accepted: 01/31/2025] [Indexed: 02/07/2025] Open
Abstract
Major Depressive Disorder (MDD) and Bipolar Disorder (BD) involve alterations of immune-inflammatory setpoints that activate the kynurenine pathway (KP), affecting serotoninergic and glutamatergic neurotransmission through indoleamine-2,3-dioxygenase (IDO) activity. This process produces metabolites like Kynurenine (Kyn), 3-Hydroxykynurenine (3-HK), Quinolinic acid (QuinA), and Kynurenic acid (KynA), these last two acting as agonist and antagonist at glutamatergic N-methyl-D-aspartate receptors (NMDARs), respectively. NMDARs, expressed in the choroid plexus (ChP) and arteriolar smooth muscle cells, regulate blood-brain-barrier permeability and cerebral artery dilation, suggesting that KP may influence neurovascular coupling, aligning blood flow with neural energy demand. KP's role in modulating vascular tone supports this hypothesis. Altered fractional amplitude of low-frequency fluctuations (fALFF) and disrupted default mode network (DMN) activity in mood disorders are linked to cognitive deficits possibly through neurovascular uncoupling like in neurological diseases. This makes fALFF and hemodynamic response function (HRF) potential indicators of these changes. We investigated KP associations with ChP volumes, functional-MRI at rest measures like spontaneous neural activity (fALFF) and hemodynamic response function (HRF) parameters within the default mode network (DMN), and cognitive performance in 42 MDD and 36 BD inpatients experiencing a depressive episode. Results revealed that lower QuinA/KynA ratios and higher KynA levels predict larger ChP volumes. Higher KYN and 3-HK levels, along with lower KynA levels, were associated with increased DMN fALFF and shorter time-to-peak (TTP) in HRF, suggesting altered neurovascular coupling. Mediation analyses indicated that KP metabolites influenced cognitive performance through their effects on resting state measures, affecting global cognitive functioning score, verbal fluency, and psychomotor coordination. These findings suggest that KP metabolites modulate brain function and structure via NMDAR-mediated pathways and vascular-based mechanisms, offering insights into the cognitive impairments observed in mood disorders and identifying potential therapeutic targets.
Collapse
Affiliation(s)
- Beatrice Bravi
- Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.
| | - Chiara Verga
- Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Mariagrazia Palladini
- Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
| | - Sara Poletti
- Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
| | - Camilla Buticchi
- Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Sut Stefania
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | - Dall'Acqua Stefano
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | - Cristina Colombo
- Vita-Salute San Raffaele University, Milan, Italy; Mood Disorder Unit, IRCCS Ospedale San Raffaele, Milan, Italy
| | - Stefano Comai
- Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Italy
| | - Francesco Benedetti
- Psychiatry and Clinical Psychobiology, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy
| |
Collapse
|
13
|
Richard-Devantoy S, Inja A, Dicker M, Bertrand JA, Turecki G, Orri M, Keilp JG. Cognitive control impairment in suicide behaviors: what do we know? A systematic review and meta-analysis of Stroop in suicide behaviors. J Affect Disord 2025; 372:358-369. [PMID: 39644928 DOI: 10.1016/j.jad.2024.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2024] [Revised: 11/12/2024] [Accepted: 12/01/2024] [Indexed: 12/09/2024]
Abstract
BACKGROUND Suicidal behavior results from a complex interplay between stressful events and vulnerability factors, including cognitive deficits. Poorer performance on the Stroop task, a measure of cognitive control, has been associated with suicidal behavior in numerous studies. The objective was to conduct an updated systematic review of the literature on the Stroop task as a neuropsychological test of vulnerability to suicidal acts in patients with mood and other psychiatric disorders, while also looking at how the type (classic versus emotional) or the version (paper or computerized) of the Stroop task, as well as the characteristics of the patient (clinical population, age, sex) moderated the Stroop effect. METHODS A search on Medline, Embase, PsycInfo databases, and article references was performed. 53 studies (6781 participants) met the selection criteria. Interference time and errors of the Stroop Test were assessed in at least 3 studies to be analyzed. Moderators, such as the type (classic versus emotional) of the Stroop task and the characteristics of the patient (clinical population, age, sex) were also assessed. RESULTS Interference time on Stroop performance was lower in suicide attempters than in patient controls (g = 0.20; 95%CI [0.10-0.30]) and healthy controls (g = 0.79; 95 % CI [0.29-1.29]), with patient controls scoring lower than healthy controls (g = -0.63; 95%CI [-1.01-0.25]). This was moderated by age and having a mood disorder. In terms of interference errors, suicide attempters performed worse than healthy controls (g = 0.57; 95%CI [0.01-1.15]) but did not perform differently from patient controls (g = 0.20; 95 % CI [-0.06-0.45]). Patient controls also did not score differently than healthy controls (g = -0.18; 95 % CI [-0.54-0.18]). There was a significant moderation effect for the type (i.e., original Stroop task) and version (i.e., paper format) of the Stroop task, and for some characteristics of the patient (i.e., older patients and having a mood disorder). CONCLUSIONS Cognitive control impairment was associated with a history of suicidal behavior in patients, especially in older populations and those with mood disorders, however this result was moderated by outcome measure (interference time vs. errors), the type (i.e., original Stroop task) and the version (i.e., paper format) of the Stroop task. Cognitive control processes may be an important factor of suicidal vulnerability. Choosing the right neurocognitive test in the right population to detect suicide vulnerability is important direction for future research.
Collapse
Affiliation(s)
- Stéphane Richard-Devantoy
- McGill University & Douglas Mental Health Research Institute, McGill Group for Suicide Studies, Montréal, Québec, Canada; CISSS des Laurentides, Department of Psychiatry, Saint-Jérôme, Canada.
| | - Ayla Inja
- McGill University & Douglas Mental Health Research Institute, McGill Group for Suicide Studies, Montréal, Québec, Canada
| | - Marina Dicker
- McGill University & Douglas Mental Health Research Institute, McGill Group for Suicide Studies, Montréal, Québec, Canada
| | - Josie-Anne Bertrand
- Douglas Research Center, Douglas Mental Health Research Institute, Montréal, Québec, Canada; CRIUMG, 4565, Chemin Queen-Mary, Montréal, Québec, Canada
| | - Gustavo Turecki
- McGill University & Douglas Mental Health Research Institute, McGill Group for Suicide Studies, Montréal, Québec, Canada
| | - M Orri
- McGill University & Douglas Mental Health Research Institute, McGill Group for Suicide Studies, Montréal, Québec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, School of Population and Global Health, McGill University, Montreal, Quebec, Canada; Danish Research Institute for Suicide Prevention, Mental Health Centre Copenhagen, Copenhagen, Denmark
| | - John G Keilp
- Department of Neuroscience, New York State Psychiatric Institute, New York, NY, United States; Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY, United States
| |
Collapse
|
14
|
Corsi-Zuelli F, Donohoe G, Griffiths SL, Del-Ben CM, Watson AJ, Burke T, Lalousis PA, McKernan D, Morris D, Kelly J, McDonald C, Patlola SR, Pariante C, Barnes NM, Khandaker GM, Suckling J, Deakin B, Upthegrove R, Dauvermann MR. Depressive and Negative Symptoms in the Early and Established Stages of Schizophrenia: Integrating Structural Brain Alterations, Cognitive Performance, and Plasma Interleukin 6 Levels. BIOLOGICAL PSYCHIATRY GLOBAL OPEN SCIENCE 2025; 5:100429. [PMID: 39911538 PMCID: PMC11795630 DOI: 10.1016/j.bpsgos.2024.100429] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2024] [Revised: 11/18/2024] [Accepted: 11/22/2024] [Indexed: 02/07/2025] Open
Abstract
Background Depressive and negative symptoms are related to poor functional outcomes in schizophrenia. Cognitive deficits, reduced brain cortical thickness and volumes, and inflammation may contribute to depressive and negative symptoms, but pharmacological treatment and disease progression may confound the associations. Methods We evaluated whether higher plasma interleukin 6 (IL-6) levels would be associated with more severe negative or depressive symptoms in schizophrenia and explored illness stage utilizing early (BeneMin [Benefit of Minocycline on Negative Symptoms of Psychosis: Extent and Mechanism], n = 201, 72.8% male) and established (iRELATE [Immune Response & Social Cognition in Schizophrenia], n = 94, 67.3% male) schizophrenia cohorts. Using structural equation modeling in a subsample (iRELATE: n = 42, 69.0% male; BeneMin: n = 102, 76.5% male) with data on structural brain metrics (cortical thickness and volume), general cognitive performance, and plasma IL-6 levels, we assessed the interrelationships between these variables on depressive and negative symptom severity in early and established schizophrenia samples combined and in early schizophrenia only. All analyses were adjusted for sex, age, and chlorpromazine equivalent dose. Results Higher plasma IL-6 levels were related to more severe depressive symptoms in early schizophrenia (p < .05) and negative symptoms in established schizophrenia (p < .05). Structural equation modeling findings in early and established schizophrenia samples combined and early schizophrenia only showed that the interrelationship between higher plasma IL-6 levels, structural brain metrics, and general cognitive performance did not predict the severity of depressive and negative symptoms (p > .05). Higher plasma IL-6 levels and lower general cognitive performance were associated with reduced brain metrics (p < .05). Conclusions Our results indicate that higher plasma IL-6 levels may be differently associated with the severity of depressive and negative symptoms dependent on the illness stage. Future work identifying elevated levels of inflammation in larger samples may allow stratification and personalized intervention by subgroups who are at risk of poor outcomes.
Collapse
Affiliation(s)
- Fabiana Corsi-Zuelli
- Institute for Mental Health, School of Psychology, University of Birmingham, Birmingham, United Kingdom
- Department of Neurosciences and Behaviour, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
| | - Gary Donohoe
- Centre for Neuroimaging, Cognition and Genomics, School of Psychology, University of Galway, Galway, Ireland
| | - Siân Lowri Griffiths
- Institute for Mental Health, School of Psychology, University of Birmingham, Birmingham, United Kingdom
| | - Cristina M. Del-Ben
- Department of Neurosciences and Behaviour, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil
| | - Andrew J. Watson
- Department of Clinical and Motor Neuroscience, University College London, Queen Square Institute of Neurology, London, United Kingdom
| | - Tom Burke
- Centre for Neuroimaging, Cognition and Genomics, School of Psychology, University of Galway, Galway, Ireland
| | - Paris A. Lalousis
- Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, United Kingdom
| | - Declan McKernan
- Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland
| | - Derek Morris
- Centre for Neuroimaging, Cognition and Genomics, School of Psychology, University of Galway, Galway, Ireland
| | - John Kelly
- Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland
| | - Colm McDonald
- Centre for Neuroimaging, Cognition and Genomics, School of Psychology, University of Galway, Galway, Ireland
| | - Saahithh R. Patlola
- Pharmacology & Therapeutics, School of Medicine, University of Galway, Galway, Ireland
| | - Carmine Pariante
- Department of Psychological Medicine, Institute of Psychiatry, Psychology, and Neuroscience, King’s College London, London, United Kingdom
| | - Nicholas M. Barnes
- College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Golam M. Khandaker
- MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
- Centre for Academic Mental Health, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
- NIHR Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
| | - John Suckling
- Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom
- Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, United Kingdom
| | - Bill Deakin
- Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, School of the Biological Sciences, University of Manchester, Manchester, United Kingdom
| | - Rachel Upthegrove
- Institute for Mental Health, School of Psychology, University of Birmingham, Birmingham, United Kingdom
- Department of Psychiatry, University of Oxford, Oxford, United Kingdom
| | - Maria R. Dauvermann
- Institute for Mental Health, School of Psychology, University of Birmingham, Birmingham, United Kingdom
| |
Collapse
|
15
|
Szücs A, Perry-Falconi MA, O'Brien EJ, Keilp JG, Bridge JA, Maier AB, Galfalvy H, Szanto K. Objective and subjective suicidal intent are differentially associated with attempt lethality based on age of onset of suicidal behavior. Sci Rep 2025; 15:5621. [PMID: 39955394 PMCID: PMC11829946 DOI: 10.1038/s41598-025-89844-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2024] [Accepted: 02/07/2025] [Indexed: 02/17/2025] Open
Abstract
Predicting the medical seriousness, or lethality, of suicide attempts remains challenging for clinicians, as impulsive and planned attempts can both be fatal and risk may vary with age and suicidal intent. We investigated whether attempt lethality is driven by practical preparedness (objective suicidal intent) and/or psychological resolve (subjective suicidal intent) and whether these associations vary with age of onset of suicidal behavior. The study used a cross-sectional lifespan sample (N = 95; age range 16-76 years) with current depression and recent suicidal behavior (≤ 5 years). Linear regression models indicated that older age of onset of suicidal behavior (B = 0.86, SE = 0.20, p < 0.001), and both higher objective intent (B = 0.69, SE = 0.19, p < 0.001) and subjective intent (B = 0.50, SE = 0.20, p = 0.014) were associated with more severe lethality at the most recent attempt, although the association with subjective intent was driven by its shared portion with objective intent. The association between objective intent and lethality was stronger with older age of onset (interaction B = 0.75, SE = 0.20, p < 0.001), whereas the association between subjective intent and lethality was stronger with younger age of onset (interaction B = - 0.42, SE = 0.20, p = 0.036). Our findings suggest that contextualizing suicidal intentions with age of onset, rather than age at the current suicidal crisis, can help clinicians better appraise suicide risk.
Collapse
Affiliation(s)
- Anna Szücs
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
- Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
- Department of Family Medicine, National University Health System, Singapore, Singapore.
| | | | - Emma J O'Brien
- Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
- Department of Psychology, Louisiana State University, Baton Rouge, LA, USA
| | - John G Keilp
- Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA
- Department of Molecular Imaging and Neuropathology, New York State Psychiatric Institute, New York, NY, USA
| | - Jeffrey A Bridge
- Departments of Pediatrics and Psychiatry and Behavioral Health, College of Medicine, Ohio State University, Columbus, OH, USA
- Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA
| | - Andrea B Maier
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- Faculty of Behavioural and Movement Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Hanga Galfalvy
- Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA
- Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA
| | - Katalin Szanto
- Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
| |
Collapse
|
16
|
Cattarinussi G, Segre G, Biaggi A, Hazelgrove K, Sambataro F, Russo M, Lawrence A, Fusté M, Mehta MA, Seneviratne G, Craig MC, Miele M, Pawlby S, Conroy S, Pariante CM, Dazzan P. Neuropsychological performance in women at risk of postpartum depression and postpartum psychosis. Arch Womens Ment Health 2025; 28:55-65. [PMID: 39214910 PMCID: PMC11762223 DOI: 10.1007/s00737-024-01510-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2024] [Accepted: 08/20/2024] [Indexed: 09/04/2024]
Abstract
PURPOSE While neuropsychological deficits are commonly observed in affective and psychotic disorders, this remains unexplored in these disorders when they occur during pregnancy and the postpartum period. METHODS A neuropsychological test battery was administered to women defined at risk of postpartum depression (PD, N = 53) because having either a current or past diagnosis of major depressive disorder, women at risk of postpartum psychosis (PP, N = 43) because of a diagnosis of bipolar disorder or schizoaffective disorder and/or a previous episode of PP and women not at risk (NR, N = 48) in the third trimester of pregnancy. Generalized and specific cognitive abilities were compared between groups. RESULTS Women at risk of PP presented worse executive functions and processing speed compared to NR and worse performance compared to women at risk of PD across all cognitive domains. In addition, women at risk of PP who developed a psychiatric relapse in the first four weeks post-partum showed worse verbal learning and memory, visual memory, executive functions and processing speed in pregnancy compared to NR, whereas women at risk of PP who remained well presented neuropsychological performance that was intermediate between that of the women NR and those at risk of PP who developed symptoms. There were no differences in performance between women at risk of PD and the NR women, even if 31 women at risk of PD presented depressive symptoms at the time of cognitive assessment. CONCLUSIONS Our findings in women at risk of PP align with neuropsychological findings in individuals with, or at risk of psychosis unrelated to pregnancy. In addition, initial evidence that women at risk of PP who develop a psychiatric relapse in the postpartum show a particularly poor neuropsychological performance in pregnancy suggests that this could be considered part of a phenotype for the disease and help guiding future preventive strategies in this clinical population. In women at risk of PD, the presence of depressive symptoms did not influence cognitive performance.
Collapse
Affiliation(s)
- Giulia Cattarinussi
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- Department of Neuroscience (DNS), Padua Neuroscience Center, University of Padova, Padua, Italy
| | - Giulia Segre
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Alessandra Biaggi
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy
| | - Katie Hazelgrove
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Fabio Sambataro
- Department of Neuroscience (DNS), Padua Neuroscience Center, University of Padova, Padua, Italy
| | - Manuela Russo
- Centre for Implementation Science, Health Service and Population Research Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Andrew Lawrence
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK
| | - Montserrat Fusté
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Mitul A Mehta
- National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK
- Centre for Neuroimaging Sciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Gertrude Seneviratne
- South London and Maudsley NHS Foundation Trust Channi Kumar Mother and Baby Unit, Bethlem Royal Hospital, London, UK
| | - Michael C Craig
- National Female Hormone Clinic, Maudsley Hospital, SLaM NHS Foundation Trust, and Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Maddalena Miele
- Perinatal Mental Health Service, St Mary's Hospital, Imperial College London and Central North West London NHS Foundation Trust, London, UK
| | - Susan Pawlby
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Susan Conroy
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - Carmine M Pariante
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
- National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK
| | - Paola Dazzan
- Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
- National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, London, UK.
| |
Collapse
|
17
|
Xu C, Tao Y, Lin Y, Zhu J, Li Z, Li J, Wang M, Huang T, Shi C. Parsing the heterogeneity of depression: a data-driven subgroup derived from cognitive function. Front Psychiatry 2025; 16:1537331. [PMID: 39950172 PMCID: PMC11821656 DOI: 10.3389/fpsyt.2025.1537331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/30/2024] [Accepted: 01/13/2025] [Indexed: 02/16/2025] Open
Abstract
Background Increasing evidences suggests that depression is a heterogeneous clinical syndrome. Cognitive deficits in depression are associated with poor psychosocial functioning and worse response to conventional antidepressants. However, a consistent profile of neurocognitive abnormalities in depression remains unclear. Objective We used data-driven parsing of cognitive performance to reveal subgroups present across depressed individuals and then investigate the change pattern of cognitive subgroups across the course in follow-up. Method We assessed cognition in 163 patients with depression using The Chinese Brief Cognitive Test(C-BCT) and the scores were compared with those of 196 healthy controls (HCs). 58 patients were reassessed after 8 weeks. We used K-means cluster analysis to identify cognitive subgroups, and compared clinical variables among these subgroups. A linear mixed-effects model, incorporating time and group (with interaction term: time × group) as fixed effects, was used to assess cognitive changes over time. Stepwise logistic regression analysis was conducted to identify risk factors associated with these subgroups. Results Two distinct neurocognitive subgroups were identified: (1) a cognitive-impaired subgroup with global impairment across all domains assessed by the C-BCT, and (2) a cognitive-preserved subgroup, exhibited intact cognitive function, with performance well within the healthy range. The cognitive-impaired subgroup presented with more severe baseline symptoms, including depressed mood, guilt, suicidality, and poorer work performance. Significant group × time interactions were observed in the Trail Making Test Part A (TMT-A) and Continuous Performance Test (CPT), but not in Symbol Coding or Digit Span tests. Despite partial improvement in TMT-A and CPT tests, the cognitive-impaired subgroup's scores remained lower than those of the cognitive-preserved subgroup across all tests at the study endpoint. Multiple regression analysis indicated that longer illness duration, lower educational levels, and antipsychotic medication use may be risk factors for cognitive impairment. Conclusion This study identifies distinguishable cognitive subgroups in acute depression, thereby confirming the presence of cognitive heterogeneity. The cognitive-impaired subgroup exhibits distinct symptoms and persistent cognitive deficits even after treatment. Screening for cognitive dysfunction may facilitate more targeted interventions. Clinical Trial Registration https://www.chictr.org, identifier ChiCTR2400092796.
Collapse
Affiliation(s)
- Chenyang Xu
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
| | - Yanbao Tao
- The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, Henan, China
| | - Yunhan Lin
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
| | - Jiahui Zhu
- Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for Mental Disorders and National Center for Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, China
| | - Zhuoran Li
- Ontario Institute for Studies in Education, University of Toronto, Toronto, ON, Canada
| | - Jiayi Li
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
| | - Mingqia Wang
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
| | - Tao Huang
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
| | - Chuan Shi
- Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China
| |
Collapse
|
18
|
Rauch AA, Soble JR, Silton RL. Anxiety symptoms are distinctly related to working memory deficits in adults with ADHD. APPLIED NEUROPSYCHOLOGY. ADULT 2025:1-13. [PMID: 39757936 DOI: 10.1080/23279095.2024.2449170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2025]
Abstract
Working memory (WM), the cognitive system that briefly stores and updates information during complex tasks, is one of the most consistently identified neurocognitive deficits in individuals with ADHD. WM deficits are linked to significant challenges in daily life. Adults with ADHD often experience co-occurring anxiety and mood disorders, which are associated with more severe clinical presentations and greater WM deficits. Disentangling how co-occurring depression and anxiety symptoms uniquely contribute to WM deficits in individuals with ADHD is critical for tailoring effective, evidence-based interventions and treatments. This study used a regression approach to explore the relationships among anxiety, depression symptoms, and WM performance in adults with ADHD (n = 439) referred for neuropsychological evaluation at a Midwestern academic medical center. ADHD diagnostic group (ADHD-I and ADHD-C; Predominately Inattentive presentation, and Combined presentation, respectively), depression symptoms, and anxiety symptoms were modeled as predictors of WM performance, with education as a covariate, as education is linked to better cognitive performance. Anxiety and education significantly predicted WM performance, while depression did not, highlighting distinct effects. Anxiety was associated with poorer WM performance, whereas education was linked to better WM. These results emphasize the need for clinical assessments that account for the impacts of specific symptoms on WM in adults with ADHD.
Collapse
Affiliation(s)
- Andrew A Rauch
- Department of Psychology, Loyola University Chicago, Chicago, IL, USA
- VA San Diego Healthcare System & UC San Diego, San Diego, CA, USA
| | - Jason R Soble
- University of Illinois at Chicago College of Medicine, Chicago, IL, USA
| | - Rebecca L Silton
- Department of Psychology, Loyola University Chicago, Chicago, IL, USA
| |
Collapse
|
19
|
Johns S, Lea-Carnall C, Shryane N, Maharani A. Depression, brain structure and socioeconomic status: A UK Biobank study. J Affect Disord 2025; 368:295-303. [PMID: 39299580 DOI: 10.1016/j.jad.2024.09.102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 09/08/2024] [Accepted: 09/14/2024] [Indexed: 09/22/2024]
Abstract
BACKGROUND Depression results from interactions between biological, social, and psychological factors. Literature shows that depression is associated with abnormal brain structure, and that socioeconomic status (SES) is associated with depression and brain structure. However, limited research considers the interaction between each of these factors. METHODS Multivariate regression analysis was conducted using UK Biobank data on 39,995 participants to examine the relationship between depression and brain volume in 23 cortical regions for the whole sample and then separated by sex. It then examined whether SES affected this relationship. RESULTS Eight out of 23 brain areas had significant negative associations with depression in the whole population. However, these relationships were abolished in seven areas when SES was included in the analysis. For females, three regions had significant negative associations with depression when SES was not included, but only one when it was. For males, lower volume in six regions was significantly associated with higher depression without SES, but this relationship was abolished in four regions when SES was included. The precentral gyrus was robustly associated with depression across all analyses. LIMITATIONS Participants with conditions that could affect the brain were not excluded. UK Biobank is not representative of the general population which may limit generalisability. SES was made up of education and income which were not considered separately. CONCLUSIONS SES affects the relationship between depression and cortical brain volume. Health practitioners and researchers should consider this when working with imaging data in these populations.
Collapse
Affiliation(s)
- Sasha Johns
- School of Social Statistics, The University of Manchester, Manchester, UK.
| | - Caroline Lea-Carnall
- Division of Psychology, Communication and Human Neuroscience, The University of Manchester, Manchester, UK
| | - Nick Shryane
- School of Social Statistics, The University of Manchester, Manchester, UK
| | - Asri Maharani
- Division of Nursing, Midwifery & Social Work, The University of Manchester, Manchester, UK
| |
Collapse
|
20
|
Flavell J, Ahern EGM, Logan B, Shaw TB, Adam RJ, McElligott CAT, Nestor PJ. Factors associated with true-positive and false-positive diagnoses of behavioural variant frontotemporal dementia in 100 consecutive referrals from specialist physicians. Eur J Neurol 2025; 32:e70036. [PMID: 39810456 PMCID: PMC11733081 DOI: 10.1111/ene.70036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2024] [Accepted: 12/19/2024] [Indexed: 01/16/2025]
Abstract
BACKGROUND The behavioural variant of frontotemporal dementia (bvFTD) is a challenging diagnosis due to overlapping symptoms with psychiatric and other neurological conditions. Accordingly, misdiagnosis is common. The present study aimed to identify clinical factors contributing to misdiagnoses of bvFTD by specialist physicians. METHODS We retrospectively analysed 100 consecutive referrals by specialist physicians (primarily psychiatrists, neurologists and geriatricians) to a tertiary cognitive disorders clinic specializing in frontotemporal lobar degenerative disorders. Patients were included if the referring specialist suspected bvFTD or if bvFTD was confirmed as the final diagnosis. Diagnostic factors were assessed by comparing the initial referral information with final clinical diagnoses. RESULTS Of the 100 patients, 34 were true-positive and 66 were false-positive for bvFTD. False-positive diagnoses were often based on misinterpretation of neuroimaging, particularly nuclear imaging (FDG-PET and HMPAO-SPECT), where subjective interpretation errors led to incorrect bvFTD diagnoses in 32 patients. Cognitive testing also contributed to misdiagnosis, with formal neuropsychological testing incorrectly leading to a bvFTD diagnosis in 20 patients. Patients with prior psychiatric histories were more likely to be misdiagnosed. Observable behavioural features of bvFTD and physical neurological signs were significantly more prevalent in true-positive patients. CONCLUSIONS Misinterpretation of neuroimaging and cognitive testing, in particular formal neuropsychological testing, significantly contributed to false-positive bvFTD diagnoses. Physicians should be cautious not to over-interpret neuroimaging and neuropsychology studies and be wary of patients with prior psychiatric histories. In contrast, greater weight should be placed on objective clinical observations of behavioural signs of bvFTD and the emergence of physical neurological signs.
Collapse
Affiliation(s)
- Joshua Flavell
- The Queensland Brain InstituteThe University of QueenslandBrisbaneQueenslandAustralia
- The Mater Memory and Cognitive Disorders ClinicThe Mater HospitalBrisbaneQueenslandAustralia
- Centre for Health Services ResearchThe University of QueenslandBrisbaneQueenslandAustralia
| | - Emily G. M. Ahern
- The Mater Memory and Cognitive Disorders ClinicThe Mater HospitalBrisbaneQueenslandAustralia
| | - Benignus Logan
- The Mater Memory and Cognitive Disorders ClinicThe Mater HospitalBrisbaneQueenslandAustralia
- Centre for Health Services ResearchThe University of QueenslandBrisbaneQueenslandAustralia
| | - Thomas B. Shaw
- Royal Brisbane and Women's Hospital and SurgicalTreatment and Rehabilitation Service (STARS), Metro North Hospital and Health ServiceBrisbaneQueenslandAustralia
- Centre for Advanced ImagingThe University of QueenslandBrisbaneQueenslandAustralia
- School of Electrical Engineering and Computer ScienceThe University of QueenslandBrisbaneQueenslandAustralia
| | - Robert J. Adam
- Centre for Health Services ResearchThe University of QueenslandBrisbaneQueenslandAustralia
- Centre for Clinical ResearchThe University of QueenslandBrisbaneAustralia
| | | | - Peter J. Nestor
- The Queensland Brain InstituteThe University of QueenslandBrisbaneQueenslandAustralia
- The Mater Memory and Cognitive Disorders ClinicThe Mater HospitalBrisbaneQueenslandAustralia
| |
Collapse
|
21
|
How EH, Chin SM, Teo CH, Parhar IS, Soga T. Accelerated biological brain aging in major depressive disorder. Rev Neurosci 2024; 35:959-968. [PMID: 39002110 DOI: 10.1515/revneuro-2024-0025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 06/26/2024] [Indexed: 07/15/2024]
Abstract
Major depressive disorder (MDD) patients commonly encounter multiple types of functional disabilities, such as social, physical, and role functioning. MDD is related to an accreted risk of brain atrophy, aging-associated brain diseases, and mortality. Based on recently available studies, there are correlations between notable biological brain aging and MDD in adulthood. Despite several clinical and epidemiological studies that associate MDD with aging phenotypes, the underlying mechanisms in the brain remain unknown. The key areas in the study of biological brain aging in MDD are structural brain aging, impairment in functional connectivity, and the impact on cognitive function and age-related disorders. Various measurements have been used to determine the severity of brain aging, such as the brain age gap estimate (BrainAGE) or brain-predicted age difference (BrainPAD). This review summarized the current results of brain imaging data on the similarities between the manifestation of brain structural changes and the age-associated processes in MDD. This review also provided recent evidence of BrainPAD or BrainAGE scores in MDD, brain structural abnormalities, and functional connectivity, which are commonly observed between MDD and age-associated processes. It serves as a basis of current reference for future research on the potential areas of investigation for diagnostic, preventive, and potentially therapeutic purposes for brain aging in MDD.
Collapse
Affiliation(s)
- Eng Han How
- 65210 Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia , Jalan Lagoon Selatan, Bandar Sunway, 47500, Selangor, Malaysia
| | - Shar-Maine Chin
- 65210 Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia , Jalan Lagoon Selatan, Bandar Sunway, 47500, Selangor, Malaysia
| | - Chuin Hau Teo
- 65210 Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia , Jalan Lagoon Selatan, Bandar Sunway, 47500, Selangor, Malaysia
| | - Ishwar S Parhar
- Center Initiatives for Training International Researchers (CiTIR), University of Toyama, Gofuku, 930-8555 Toyama, Japan
| | - Tomoko Soga
- 65210 Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia , Jalan Lagoon Selatan, Bandar Sunway, 47500, Selangor, Malaysia
| |
Collapse
|
22
|
Sakamoto MS, Thomas GA, Bradson ML, Arnett PA. Examining the role of depression on the relationship between performance-based and self-reported cognitive functioning after sport-related concussion. Arch Clin Neuropsychol 2024; 39:1390-1397. [PMID: 38798034 DOI: 10.1093/arclin/acae043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Accepted: 05/09/2024] [Indexed: 05/29/2024] Open
Abstract
OBJECTIVE Little is known about the relationship between neuropsychological test performance, cognitive symptom reporting, and depressive symptoms after sport-related concussion. Accordingly, this cross-sectional study examined these relationships in collegiate athletes. It was hypothesized that depressive symptoms would moderate and mediate the relationship between performance-based and self-reported cognitive functioning after concussion. METHODS After sustaining a sport-related concussion, 110 collegiate athletes completed a neuropsychological battery, the Post-Concussion Symptoms Scale, and the Beck Depression Inventory-Fast Screen. Neuropsychological test performance, depressive symptoms, and their interactions were entered into distinct hierarchical linear regression analyses with self-reported cognition as the dependent variable to assess moderation. Mediation was analyzed using the PROCESS macro with 5000 bootstrap samples and a 95% confidence interval. RESULTS There was a significant interaction between the mean memory composite and depressive symptoms when predicting cognitive symptom reporting, p = 0.047. Simple effects tests revealed that for athletes who had a lower memory composite score, an increase in depressive symptoms led to an increase in self-reported cognitive dysfunction, p < 0.001, ηp2 = 0.11. Depressive symptoms partially mediated the relationship between the memory composite and cognitive symptom reporting, indirect effect = -0.26, 95%CI[-0.58,0.001], but this relationship was not found for any other neurocognitive domain. CONCLUSIONS For tests of memory, depressive symptoms moderated and partially mediated the relationship between performance-based and self-reported cognitive functioning after sport-related concussion. Athletes reporting high depressive symptoms and cognitive dysfunction may need more comprehensive evaluations to inform return-to-play decisions, and depression could be a treatment target for athletes who report high levels of cognitive dysfunction after concussion.
Collapse
Affiliation(s)
- McKenna S Sakamoto
- Department of Psychology, The Pennsylvania State University, University Park, PA 16802, USA
| | - Garrett A Thomas
- Department of Psychology, The Pennsylvania State University, University Park, PA 16802, USA
| | - Megan L Bradson
- Department of Psychology, The Pennsylvania State University, University Park, PA 16802, USA
| | - Peter A Arnett
- Department of Psychology, The Pennsylvania State University, University Park, PA 16802, USA
| |
Collapse
|
23
|
Hammar Å, Ronold EH, Spurkeland MA, Ueland R, Kessler U, Oedegaard KJ, Oltedal L. Improvement of persistent impairments in executive functions and attention following electroconvulsive therapy in a case control longitudinal follow up study. BMC Psychiatry 2024; 24:832. [PMID: 39567961 PMCID: PMC11577909 DOI: 10.1186/s12888-024-06270-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2024] [Accepted: 11/08/2024] [Indexed: 11/22/2024] Open
Abstract
BACKGROUND How cognition is influenced by electroconvulsive treatment (ECT) and major depressive disorder (MDD) is still debated. The development and etiology of neurocognitive impairment in MDD were examined by investigating the cognitive profile following ECT related to the state, scar, and trait perspectives, with the former predicting improvements parallel with depressive symptoms, while the two latter expected persisting impairments. Executive functions (EF) and attention are central to cognition and alterations in these functions could influence other domains like memory. The main aims of the present study were to examine the short and long-term effects of ECT on EF and attention in patients with major depressive disorder by exploiting the rapid antidepressant effect of this treatment. METHODS A case-control longitudinal follow-up design was used to investigate the effects of unilateral brief-pulse ECT on EF and attention in patients with depression (n = 36) compared to untreated healthy controls (n = 16). EF and attention were measured pre-treatment, approximately two weeks, and six months post-treatment. RESULTS The patient group showed significantly worse performance on most tests compared to healthy controls pre-treatment, and no short- or long-term worsening of EF and attention following ECT was found. Significant improvement was identified in patients' attention, processing speed and inhibition after ECT. CONCLUSIONS The present study showed that there was no cognitive worsening after ECT treatment. An improvement in several of the tests measuring inhibition, attention, and processing speed was parallel to symptom reduction, with the former showing associations to symptom change, suggesting state-related effects from improved mood. Still, the patient group performed significantly worse on most measures both pre-treatment and at the short and long-term follow-ups, indicating prevailing trait or scar effects on cognitive functions and potential lack of practice effects. CLINICAL TRIAL NUMBER NCT04348825 (14.04.20).
Collapse
Affiliation(s)
- Åsa Hammar
- Department of Biological and Medical Psychology, University of Bergen, Alrek helseklynge Årstadveien 17, Bergen, 5020, Norway
- Department of Clinical Sciences Lund, Psychiatry, Faculty of Medicine, Lund University, Lund, Sweden
- Office for Psychiatry and Habilitation, Psychiatry Research Skåne, Region Skåne, Sweden
| | - Eivind Haga Ronold
- Department of Biological and Medical Psychology, University of Bergen, Alrek helseklynge Årstadveien 17, Bergen, 5020, Norway.
| | - Malene Alden Spurkeland
- Department of Biological and Medical Psychology, University of Bergen, Alrek helseklynge Årstadveien 17, Bergen, 5020, Norway
| | - Rita Ueland
- Department of Biological and Medical Psychology, University of Bergen, Alrek helseklynge Årstadveien 17, Bergen, 5020, Norway
| | - Ute Kessler
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
| | - Ketil J Oedegaard
- Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
| | - Leif Oltedal
- Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway
| |
Collapse
|
24
|
Morrison RL, Singh J, Daly E, Fedgchin M, Ochs-Ross R, Karcher K, Lane R, Cooper K, Sanacora G, Maruff P, Drevets WC. Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies. Int J Neuropsychopharmacol 2024; 27:pyae046. [PMID: 39514643 PMCID: PMC11561565 DOI: 10.1093/ijnp/pyae046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Accepted: 11/07/2024] [Indexed: 11/16/2024] Open
Abstract
BACKGROUND While esketamine is effective in treatment-resistant depression (TRD), detailed information about the effect of esketamine on cognition is relatively scarce. This analysis assessed the effect of short-term (3 double-blind [DB] studies: DB1, DB2, and DB4) or long-term maintenance treatment (DB3) with esketamine nasal spray (ESK) compared with a placebo (PBO) combined with active-comparator, on cognition in patients with TRD. METHODS Patients (DB1/DB2/DB3: [18-64 years, n = 747]; DB4: [65 years or older, n = 137]) with TRD received ESK (DB1/DB2/DB3: 56/84 mg; DB4: 28/56/84 mg) or PBO+newly initiated oral antidepressant (OAD) as per treatment schedules. Cognitive assessments-Cogstate battery and Hopkins Verbal Learning Test-Revised-were administered at baseline, Day 28/early withdrawal, and follow-up visits in DB1/DB2/DB4 and at 12-week intervals in the DB3 maintenance phase. Descriptive statistics were used to analyze ESK effects on cognition with effect sizes and 95% confidence intervals to express the nature and magnitude of treatment effects relative to active-comparator+PBO. Correlation between depression severity (Montgomery-Ǻsberg Depression Rating Scale scores [MADRS]) and cognition was assessed at baseline and endpoint(s). RESULTS At baseline, mild-to-moderate impairment in psychomotor function, attention, and memory (working and episodic) were evident. For each DB1/DB2/DB4, group mean performance in Z-scores for ESK+OAD and OAD+PBO groups on all cognitive tests remained similar or slightly improved from baseline at endpoint (Day 28) and follow-up assessments. Similarly, in DB3 (maintenance phase), both groups generally showed improvement in cognitive performance at endpoint(s). Correlations between MADRS scores and performance on the cognitive test battery were small at baseline and endpoint(s). CONCLUSIONS This analysis did not identify evidence of negative effects on cognition following short-term or long-term maintenance treatment with ESK+OAD in patients with TRD.
Collapse
Affiliation(s)
| | - Jaskaran Singh
- Janssen Research & Development, LLC, San Diego, California, USA
| | - Ella Daly
- Janssen Research & Development, LLC, Titusville, New Jersey, USA
| | - Maggie Fedgchin
- Janssen Research & Development, LLC, Titusville, New Jersey, USA
| | - Rachel Ochs-Ross
- Janssen Research & Development, LLC, Pennington, New Jersey, USA
| | - Keith Karcher
- Janssen Research & Development, LLC, Titusville, New Jersey, USA
| | - Rosanne Lane
- Janssen Research & Development, LLC, Pennington, New Jersey, USA
| | - Kim Cooper
- Janssen Research & Development, LLC, Spring House, Pennsylvania, USA
| | | | | | - Wayne C Drevets
- Janssen Research & Development, LLC, San Diego, California, USA
| |
Collapse
|
25
|
Dudhabhate BB, Awathale SN, Choudhary AG, Subhedar NK, Kokare DM. Deep brain stimulation targeted at lateral hypothalamus-medial forebrain bundle reverses depressive-like symptoms and related cognitive deficits in rat: Role of serotoninergic system. Neuroscience 2024; 556:96-113. [PMID: 39103042 DOI: 10.1016/j.neuroscience.2024.07.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2024] [Revised: 07/12/2024] [Accepted: 07/31/2024] [Indexed: 08/07/2024]
Abstract
The aim of the study is to understand the rationale behind the application of deep brain stimulation (DBS) in the treatment of depression. Male Wistar rats, rendered depressive with chronic unpredictable mild stress (CUMS) were implanted with electrode in the lateral hypothalamus-medial forebrain bundle (LH-MFB) and subjected to deep brain stimulation (DBS) for 4 h each day for 14 days. DBS rats, as well as controls, were screened for a range of parameters indicative of depressive state. Symptomatic features noticed in CUMS rats like the memory deficit, anhedonia, reduction in body weight and 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) levels in mPFC and elevated plasma corticosterone were reversed in rats subjected to DBS. DBS arrested CUMS induced degeneration of 5-HT cells in interfascicular region of dorsal raphe nucleus (DRif) and fibers in LH-MFB and induced dendritic proliferation in mPFC neurons. MFB is known to serve as a major conduit for the DRif-mPFC serotoninergic pathway. While the density of serotonin fibers in the LH-MFB circuit was reduced in CUMS, it was upregulated in DBS-treated rats. Furthermore, microinjection of 5-HT1A receptor antagonist, WAY100635 into mPFC countered the positive effects of DBS like the antidepressant and memory-enhancing action. In this background, we suggest that DBS at LH-MFB may exercise positive effect in depressive rats via upregulation of the serotoninergic system. While these data drawn from the experiments on rat provide meaningful clues, we suggest that further studies aimed at understanding the usefulness of DBS at LH-MFB in humans may be rewarding.
Collapse
Affiliation(s)
- Biru B Dudhabhate
- Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440 033, India
| | - Sanjay N Awathale
- Shri Vile Parle Kelavani Mandal's Institute of Pharmacy, Dhule 424 001, Maharashtra, India
| | - Amit G Choudhary
- Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440 033, India
| | - Nishikant K Subhedar
- Indian Institute of Science Education and Research (IISER), Dr. Homi Bhabha Road, Pune 411 008, India
| | - Dadasaheb M Kokare
- Department of Pharmaceutical Sciences, Rashtrasant Tukadoji Maharaj Nagpur University, Nagpur 440 033, India.
| |
Collapse
|
26
|
Little B, Flowers C, Blamire A, Thelwall P, Taylor JP, Gallagher P, Cousins DA, Wang Y. Multivariate brain-cognition associations in euthymic bipolar disorder. Bipolar Disord 2024; 26:604-616. [PMID: 39138611 DOI: 10.1111/bdi.13484] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 08/15/2024]
Abstract
BACKGROUND People with bipolar disorder (BD) tend to show widespread cognitive impairment compared to healthy controls. Impairments in processing speed (PS), attention and executive function (EF) may represent 'core' impairments that have a role in wider cognitive dysfunction. Cognitive impairments appear to relate to structural brain abnormalities in BD, but whether core deficits are related to particular brain regions is unclear and much of the research on brain-cognition associations is limited by univariate analysis and small samples. METHODS Euthymic BD patients (n = 56) and matched healthy controls (n = 26) underwent T1-weighted MRI scans and completed neuropsychological tests of PS, attention and EF. We utilised public datasets to develop normative models of cortical thickness (n = 5977) to generate robust estimations of cortical abnormalities in patients. Canonical correlation analysis was used to assess multivariate brain-cognition associations in BD, controlling for age, sex and premorbid IQ. RESULTS BD showed impairments on tests of PS, attention and EF, and abnormal cortical thickness in several brain regions compared to healthy controls. Impairments in tests of PS and EF were most strongly associated with cortical thickness in the left inferior temporal, right entorhinal and right temporal pole areas. CONCLUSION Impairments in PS, attention and EF can be observed in euthymic BD and may be related to abnormal cortical thickness in temporal regions. Future research should continue to leverage normative modelling and multivariate methods to examine complex brain-cognition associations in BD. Future research may benefit from exploring covariance between traditional brain structural morphological metrics such as cortical thickness, cortical volume and surface area.
Collapse
Affiliation(s)
- Bethany Little
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
- CNNP Lab (www.cnnp-lab.com), Interdisciplinary Computing and Complex Biosystems Group, School of Computing, Newcastle University, Newcastle upon Tyne, UK
| | - Carly Flowers
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Andrew Blamire
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Peter Thelwall
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - John-Paul Taylor
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Peter Gallagher
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - David Andrew Cousins
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
- Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK
| | - Yujiang Wang
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
- CNNP Lab (www.cnnp-lab.com), Interdisciplinary Computing and Complex Biosystems Group, School of Computing, Newcastle University, Newcastle upon Tyne, UK
| |
Collapse
|
27
|
Woo YS, Lee KU, Hahn C, McIntyre RS, Teopiz KM, Bahk WM. Psychometric Properties of the Korean Version of THINC-integrated Tool (THINC-it-K): A Tool for Screening Assessment of Cognitive Function in Patients with Major Depressive Disorder. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE : THE OFFICIAL SCIENTIFIC JOURNAL OF THE KOREAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY 2024; 22:458-465. [PMID: 39069685 PMCID: PMC11289603 DOI: 10.9758/cpn.23.1135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 10/25/2023] [Indexed: 07/30/2024]
Abstract
Objective : The present study was performed to investigate the validity and reliability of the Korean version of the THINC-it tool (THINC-it-K) in adult patients with major depressive disorder (MDD). Methods : Subjects aged 19-65 years with recurrent MDD experiencing moderate to severe major depressive episode (n = 44) were evaluated and compared to age and sex matched healthy controls (n = 44). Subjects completed the THINC-it-K which includes variants of the Identification Task (IDN) using Choice Reaction Time, One-Back Test, Digit Symbol Substitution Test, Trail Making Test-Part B, and the Perceived Deficits Questionnaire for Depression-5-item (PDQ-5-D). Results : A total of 75.0% of patients with MDD exhibited cognitive performance 1 standard deviation or below. The differences in Spotter (p = 0.001), Codebreaker (p = 0.001), PDQ-5-D (p < 0.001) and objective THINC-it-K composite score (p = 0.002) were significant between the two groups. Concurrent validity of the THINC-it-K based on a calculated composite score was good (r = 0.856, p < 0.001), and ranges for each component tests were from 0.076 (IDN) to 0.928 (PDQ-5-D). Conclusion : The THINC-it-K exhibits good reliability and validity in adults with MDD. It could be a useful tool for the measurement of cognitive deficits in persons with MDD and should be implemented in clinical practice.
Collapse
Affiliation(s)
- Young Sup Woo
- Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Kyoung-Uk Lee
- Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Changtae Hahn
- Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Roger S. McIntyre
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada
| | - Kayla M. Teopiz
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada
| | - Won-Myong Bahk
- Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea
| |
Collapse
|
28
|
Marquez-Arrico JE, Catalán-Aguilar J, Navarro JF, Adan A. Neurocognitive and clinical profile of male patients with substance use disorder in early remission phase with and without comorbid depression. Prog Neuropsychopharmacol Biol Psychiatry 2024; 134:111085. [PMID: 39002929 DOI: 10.1016/j.pnpbp.2024.111085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Revised: 06/19/2024] [Accepted: 07/08/2024] [Indexed: 07/15/2024]
Abstract
Substance Use Disorder (SUD) represents one of the most frequent conditions worldwide which commonly coexists with major depressive disorder (MDD). This comorbidity (SUD + MDD) is one of the most prevalent with patients showing certain social and clinical characteristics that could lead to a worsening of their cognitive performance. However, despite these particularities, only a few studies have addressed the possible differences in cognitive performance between patients with SUD + MDD compared with those with SUD-only patients. Therefore, the aim of this study is to examine the clinical and cognitive profile of patients with SUD + MDD vs. SUD-only who are in early remission phase. For this purpose, 271 male patients underwent a clinical and neuropsychological assessment (SUD + MDD group: N = 101; SUD-only group: N = 170). Results indicated that SUD + MDD patients showed worse cognitive performance than SUD in visuospatial reasoning, verbal memory and learning, recognition, and processing speed even after a 3-month period of abstinence. Furthermore, these patients exhibited more self-reported prefrontal symptoms, as well as worse social and clinical conditions. This study indicates that the neurocognitive and clinical profile of patients with SUD + MDD could represent a risk since their characteristics have been associated with poorer recovery and prognosis. Our results could be helpful in clinical practice highlighting the need for cognitive remediation strategies in these populations, providing information that would allow the implementation of more appropriate treatments and preventive strategies.
Collapse
Affiliation(s)
- Julia E Marquez-Arrico
- Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain; Institute of Neurosciences, University of Barcelona, 08035 Barcelona, Spain
| | - Judit Catalán-Aguilar
- Department of Psychobiology, Psychology Center, Universitat de València, Av. Blasco Ibáñez, 21, 46010 Valencia, Spain; Institut d'Investigació en Psicologia dels Recursos Humans, del Desenvolupament Organitzacional i de la Qualitat de Vida Laboral (Idocal), Universitat de València, Av. Blasco Ibáñez, 21, 46010 Valencia, Spain
| | - José Francisco Navarro
- Department of Psychobiology, School of Psychology, University of Málaga, Campus de Teatinos s/n, 29071 Málaga, Spain
| | - Ana Adan
- Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain; Institute of Neurosciences, University of Barcelona, 08035 Barcelona, Spain.
| |
Collapse
|
29
|
Valentim JT, da Silva DMA, Capibaribe VCC, Sales ISL, Rebouças MDO, Araújo LA, Chaves RDC, Campelo MDS, Ribeiro MENP, de Sousa FCF. Carvacrol alleviates CUMS-induced depressive-like behaviors and cognitive impairment by reducing oxidative stress and neuroinflammation in mice. Behav Brain Res 2024; 472:115135. [PMID: 38964616 DOI: 10.1016/j.bbr.2024.115135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2024] [Revised: 06/21/2024] [Accepted: 07/01/2024] [Indexed: 07/06/2024]
Abstract
The present study aimed to evaluate the protective potential of carvacrol against depressive-like behavior and cognitive impairment prompted by chronic unpredictable mild stress (CUMS) in mice. The animals were divided into six groups: Control (non-stressed), CARV (carvacrol at 50 mg/kg, p.o.), FLU (fluoxetine at 10 mg/kg, p.o.), CUMS (stressed), CUMS + CARV and CUMS + FLU, and the groups with CUMS were subjected to different stressors for 28 days. After treatment, mice underwent behavioral testing (open field, forced swimming, sucrose preference, social interaction, novel object recognition and Y-maze) and brain areas were removed for oxidative stress (MDA, nitrite/nitrate and GSH levels) and cytokine (IL-1β and TNF-α) content assays. The results revealed that CARV administration reversed depressive-like behavior and significantly ameliorated the cognitive deficit induced by CUMS, as well as was able to attenuate oxidative stress (decreased MDA and nitrite/nitrate levels and increased GSH levels). In addition, a significant reduction in hippocampal IL-1β and TNF-α levels was observed, demonstrating a potential anti-neuroinflammatory activity. Taken together, the antioxidant and anti-inflammatory activities observed in this study indicate that CARV is a promising drug for antidepressant treatment.
Collapse
Affiliation(s)
- José Tiago Valentim
- Laboratory of Neuropsychopharmacology, Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Brazil
| | - Daniel Moreira Alves da Silva
- Laboratory of Neuropsychopharmacology, Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Brazil
| | - Victor Celso Cavalcanti Capibaribe
- Laboratory of Neuropsychopharmacology, Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Brazil
| | - Iardja Stéfane Lopes Sales
- Laboratory of Neuropsychopharmacology, Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Brazil
| | - Manoela de Oliveira Rebouças
- Laboratory of Neuropsychopharmacology, Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Brazil
| | - Layla Alves Araújo
- Laboratory of Neuropsychopharmacology, Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Brazil
| | - Raquell de Castro Chaves
- Laboratory of Neuropsychopharmacology, Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Brazil
| | - Matheus da Silva Campelo
- Polymers and Materials Innovation Laboratory, Department of Organic and Inorganic Chemistry, Science Center, Federal University of Ceará, Fortaleza, Ceará, Brazil
| | - Maria Elenir Nobre Pinho Ribeiro
- Polymers and Materials Innovation Laboratory, Department of Organic and Inorganic Chemistry, Science Center, Federal University of Ceará, Fortaleza, Ceará, Brazil.
| | - Francisca Cléa Florenço de Sousa
- Laboratory of Neuropsychopharmacology, Department of Physiology and Pharmacology, Drug Research and Development Center, Federal University of Ceará, Fortaleza, Brazil.
| |
Collapse
|
30
|
Koterba CH, Considine CM, Becker JH, Hoskinson KR, Ng R, Vargas G, Basso MR, Puente AE, Lippa SM, Whiteside DM. Neuropsychology practice guidance for the neuropsychiatric aspects of Long COVID. Clin Neuropsychol 2024:1-29. [PMID: 39177216 DOI: 10.1080/13854046.2024.2392943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Accepted: 08/12/2024] [Indexed: 08/24/2024]
Abstract
Objective: The coronavirus disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has had a profound global impact on individual health and well-being in adults and children. While most fully recover from COVID-19, a relatively large subgroup continues to experience persistent physical, cognitive, and emotional/behavioral symptoms beyond the initial infection period. The World Health Organization has termed this phenomenon "Post-COVID-19 Condition" (PCC), better known as "Long COVID." Due to the cognitive and psychosocial symptoms, neuropsychologists often assess and recommend treatment for individuals with Long COVID. However, guidance for neuropsychologists' involvement in clinical care, policy-making, and research has not yet been developed. The authors of this manuscript convened to address this critical gap and develop guidance for clinical neuropsychologists working with patients presenting with Long COVID. Method: Authors include pediatric and adult neuropsychologists with expertise in Long COVID and behavioral health. All authors have been engaged in clinical and research efforts examining the impact of COVID-19. Authors summarized the literature-to-date pertinent to the neuropsychiatric sequelae of Long COVID and developed guidance for neuropsychologists working with individuals with Long COVID. Conclusions: Research findings regarding neuropsychiatric symptoms associated with Long COVID are mixed and limited by methodological differences. As they practice and conduct research, neuropsychologists should remain mindful of the evolving and tenuous nature of the literature.
Collapse
Affiliation(s)
- Christine H Koterba
- Department of Neuropsychology, Nationwide Children's Hospital, Columbus, OH, USA
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA
| | - Ciaran M Considine
- Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Jacqueline H Becker
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Kristen R Hoskinson
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA
- Center for Biobehavioral Health, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, USA
| | - Rowena Ng
- Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, MD, USA
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Gray Vargas
- Department of Neuropsychology, Kennedy Krieger Institute, Baltimore, MD, USA
| | - Michael R Basso
- Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA
| | | | - Sara M Lippa
- National Intrepid Center of Excellence, Walter Reed National Military Medical Center, Bethesda, MD, USA
- Department of Neuroscience, Uniformed Services University of the Health Sciences, Bethesda, MD, USA
| | - Douglas M Whiteside
- Department of Rehabilitation Medicine, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
31
|
Lundervold AJ, Billing JE, Berentsen B, Lied GA, Steinsvik EK, Hausken T, Lundervold A. Decoding IBS: a machine learning approach to psychological distress and gut-brain interaction. BMC Gastroenterol 2024; 24:267. [PMID: 39148020 PMCID: PMC11325751 DOI: 10.1186/s12876-024-03355-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Accepted: 08/06/2024] [Indexed: 08/17/2024] Open
Abstract
PURPOSE Irritable bowel syndrome (IBS) is a diagnosis defined by gastrointestinal (GI) symptoms like abdominal pain and changes associated with defecation. The condition is classified as a disorder of the gut-brain interaction (DGBI), and patients with IBS commonly experience psychological distress. The present study focuses on this distress, defined from reports of fatigue, anxiety, depression, sleep disturbances, and performance on cognitive tests. The aim was to investigate the joint contribution of these features of psychological distress in predicting IBS versus healthy controls (HCs) and to disentangle clinically meaningful subgroups of IBS patients. METHODS IBS patients ( n = 49 ) and HCs ( n = 28 ) completed the Chalder Fatigue Scale (CFQ), the Hamilton Anxiety and Depression Scale (HADS), and the Bergen Insomnia Scale (BIS), and performed tests of memory function and attention from the Repeatable Battery Assessing Neuropsychological Symptoms (RBANS). An initial exploratory data analysis was followed by supervised (Random Forest) and unsupervised (K-means) classification procedures. RESULTS The explorative data analysis showed that the group of IBS patients obtained significantly more severe scores than HCs on all included measures, with the strongest pairwise correlation between fatigue and a quality measure of sleep disturbances. The supervised classification model correctly predicted belongings to the IBS group in 80% of the cases in a test set of unseen data. Two methods for calculating feature importance in the test set gave mental and physical fatigue and anxiety the strongest weights. An unsupervised procedure with K = 3 showed that one cluster contained 24% of the patients and all but two HCs. In the two other clusters, their IBS members were overall more impaired, with the following differences. One of the two clusters showed more severe cognitive problems and anxiety symptoms than the other, which experienced more severe problems related to the quality of sleep and fatigue. The three clusters were not different on a severity measure of IBS and age. CONCLUSION The results showed that psychological distress is an integral component of IBS symptomatology. The study should inspire future longitudinal studies to further dissect clinical patterns of IBS to improve the assessment and personalized treatment for this and other patient groups defined as disorders of the gut-brain interaction. The project is registered at https://classic. CLINICALTRIALS gov/ct2/show/NCT04296552 20/05/2019.
Collapse
Affiliation(s)
- Astri J Lundervold
- Department of Biological and Medical Psychology, Universtity of Bergen, Bergen, 5020, Norway.
| | - Julie E Billing
- Department of Biological and Medical Psychology, Universtity of Bergen, Bergen, 5020, Norway
| | - Birgitte Berentsen
- National Center for Functional Gastrointestinal Disorders, Department of Medicine, Haukeland University Hospital, Bergen, 5021, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, 5020, Norway
| | - Gülen A Lied
- National Center for Functional Gastrointestinal Disorders, Department of Medicine, Haukeland University Hospital, Bergen, 5021, Norway
- Center for Nutrition, Department of Clinical Medicine, University of Bergen, Bergen, 5020, Norway
| | - Elisabeth K Steinsvik
- National Center for Functional Gastrointestinal Disorders, Department of Medicine, Haukeland University Hospital, Bergen, 5021, Norway
- Department of Clinical Medicine, University of Bergen, Bergen, 5020, Norway
| | - Trygve Hausken
- National Center for Functional Gastrointestinal Disorders, Department of Medicine, Haukeland University Hospital, Bergen, 5021, Norway
| | - Arvid Lundervold
- Department of Biomedicine, University of Bergen, Bergen, 5020, Norway
- Medical-AI, Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, 5021, Norway
| |
Collapse
|
32
|
Yavuz BE, Turan S, Mutlu C, Çamlı ŞE. A comparison of the social cognition and neurocognitive characteristics of adolescents with suicide behavior, adolescent with depression and healthy controls. Suicide Life Threat Behav 2024; 54:785-797. [PMID: 38738815 DOI: 10.1111/sltb.13090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 03/31/2024] [Accepted: 04/18/2024] [Indexed: 05/14/2024]
Abstract
INTRODUCTION Deficits in neurocognition and social-cognition have been suggested to be an endophenotype for suicidal behavior. We aimed to compare the social-cognition and neurocognitive characteristics of adolescents diagnosed with depression with and without suicidal behavior and to investigate whether these functions predict suicide. METHOD Adolescents diagnosed with Major Depressive Disorder (MDD) with suicidal behavior (n = 42); MDD without suicidal behavior (n = 44) and age- and sex-matched controls (n = 43) were included. The University of Pennsylvania Computerized Neurobehavioral Test Battery and Autism Spectrum Screening Questionnaire (ASSQ) were used to evaluate social-cognition and neurocognitive characteristics. RESULTS Several neurocognitive domain values of MDD groups, were significantly different from the control group. Neutral emotion recognition task (p = 0.025) and ASSQ scores were found to be significantly impaired in the patient groups (p < 0.001). Logistic regression analysis showed that, only the increase in the Suicide Probability Scale score was found to be significant as a risk factor predicting suicide (p = 0.007, OR: 1.246). CONCLUSION While the neurocognitive and social-cognitive performances of adolescents with MDD were significantly lower than the control group, these performances in the two depression groups were similar. When the predictors of suicidal behavior were examined, it was found that only the increase in suicidal ideation scores predicted suicide.
Collapse
Affiliation(s)
- B Ece Yavuz
- Department of Child and Adolescent Psychiatry, TC Sağlık Bakanlığı Cizre Dr. Selahattin Cizrelioğlu Devlet Hastanesi, Şırnak, Turkey
| | - Serkan Turan
- Department ofChild and Adolescent Psychiatry, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey
| | - Caner Mutlu
- Department ofChild and Adolescent Psychiatry, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey
| | - Şafak Eray Çamlı
- Department ofChild and Adolescent Psychiatry, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey
| |
Collapse
|
33
|
Fiorillo A, Albert U, Dell'Osso B, Pompili M, Sani G, Sampogna G. The clinical utility and relevance in clinical practice of DSM-5 specifiers for major depressive disorder: A Delphi expert consensus study. Compr Psychiatry 2024; 133:152502. [PMID: 38810371 DOI: 10.1016/j.comppsych.2024.152502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2023] [Revised: 05/06/2024] [Accepted: 05/18/2024] [Indexed: 05/31/2024] Open
Abstract
Major depressive disorder (MDD) is a heterogeneous syndrome, associated with different levels of severity and impairment on the personal functioning for each patient. Classification systems in psychiatry, including ICD-11 and DSM-5, are used by clinicians in order to simplify the complexity of clinical manifestations. In particular, the DSM-5 introduced specifiers, subtypes, severity ratings, and cross-cutting symptom assessments allowing clinicians to better describe the specific clinical features of each patient. However, the use of DSM-5 specifiers for major depressive disorder in ordinary clinical practice is quite heterogeneous. The present study, using a Delphi method, aims to evaluate the consensus of a representative group of expert psychiatrists on a series of statements regarding the clinical utility and relevance of DSM-5 specifiers for major depressive disorder in ordinary clinical practice. Experts reached an almost perfect agreement on statements related to the use and clinical utility of DSM-5 specifiers in ordinary clinical practice. In particular, a complete consensus was found regarding the clinical utility for ordinary clinical practice of using DSM-5 specifiers. The use of specifiers is considered a first step toward a "dimensional" approach to the diagnosis of mental disorders.
Collapse
Affiliation(s)
- Andrea Fiorillo
- Department of Psychiatry, University of Campania "L. Vanvitelli", Naples, Italy
| | - Umberto Albert
- Department of Medicine, Surgery and Health Sciences, University of Trieste and Department of Mental Health, Azienda Sanitaria Universitaria Giuliano Isontina - ASUGI, Italy
| | - Bernardo Dell'Osso
- Neuroscience Research Center, Department of Biomedical and Clinical Sciences and Aldo Ravelli Center for Neurotechnology and Brain Therapeutic, University of Milan, Milano, Italy; Department of Psychiatry and Behavioural Sciences, Stanford University, USA
| | - Maurizio Pompili
- Department of Neurosciences, Mental Health and Sensory Organs, Faculty of Medicine and Psychology, Sapienza University of Rome, Italy
| | - Gabriele Sani
- Department of Neuroscience, Section of Psychiatry, University Cattolica del Sacro Cuore, Rome, Italy; Department of Neuroscience, Sensory organs and Thorax, Department of Psychiatry, Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy
| | - Gaia Sampogna
- Department of Psychiatry, University of Campania "L. Vanvitelli", Naples, Italy
| |
Collapse
|
34
|
Liu X, Ngoubene-Atioky AJ, Yang X, Deng Y, Tang J, Wu L, Huang J, Zheng Y, Fang J, Kaur A, Chen L. The effect of childhood family adversity on adulthood depression among Chinese older migrant workers: gender differences in the mediating role of social-ecological systems. BMC Public Health 2024; 24:2005. [PMID: 39061001 PMCID: PMC11282819 DOI: 10.1186/s12889-024-19397-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Accepted: 07/08/2024] [Indexed: 07/28/2024] Open
Abstract
BACKGROUND Older migrant workers (OMWs) in China face unique challenges rooted in their early life experiences, which increase their vulnerability to psychological and behavioral problems in adulthood. By utilizing the cumulative disadvantage model and the social-ecological systems theory, this study explored the effect of childhood family adversity on adulthood depression in the mediating roles of OMWs' social-ecological microsystem and mesosystem and further examined gender differences in these associations. METHODS Data were collected from the China Health and Retirement Longitudinal Study (CHARLS), involving a sample of 4,309 OMWs aged 50 and above. The measures included the Center for Epidemiological Research Depression Scale, childhood family adversity, socioeconomic status, marital quality, and physical and cognitive health. RESULTS Childhood family adversity was positively associated with adulthood depression among OMWs. Social microsystem (physical and cognitive health) and mesosystem (marital quality and socioeconomic status) factors significantly mediated this relationship. Multi-group analysis revealed that the mediating effects of marital quality and socioeconomic status were stronger for female OMWs, while the mediating effects of physical and cognitive health were stronger for male OMWs. CONCLUSIONS The findings suggest that childhood family adversity has a lasting impact on the mental health of OMWs, and that social-ecological systems factors play an important role in this relationship. The study also highlights the need for gender-specific interventions to address the mental health needs of OMWs.
Collapse
Affiliation(s)
- Xiaoyue Liu
- School of Mental Health, Wenzhou Medical University, Wenzhou, China
| | | | - Xudong Yang
- School of Mental Health, Wenzhou Medical University, Wenzhou, China
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, China
| | | | - Jiayi Tang
- School of Mental Health, Wenzhou Medical University, Wenzhou, China
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, China
| | - Liujun Wu
- School of Mental Health, Wenzhou Medical University, Wenzhou, China
- Cixi Biomedical Research Institute, Wenzhou Medical University, Ningbo, China
| | - Jiahui Huang
- School of Mental Health, Wenzhou Medical University, Wenzhou, China
| | - Yawen Zheng
- School of Mental Health, Wenzhou Medical University, Wenzhou, China
| | - Juan Fang
- School of Mental Health, Wenzhou Medical University, Wenzhou, China
| | - Amrita Kaur
- School of Psychology, Wenzhou-Kean University, Wenzhou, China.
| | - Li Chen
- School of Mental Health, Wenzhou Medical University, Wenzhou, China.
- The affiliated Wenzhou Kangning Hospital, Wenzhou Medical University, Wenzhou, China.
| |
Collapse
|
35
|
Gillespie KM, Dymond AH, Li X, Schweitzer D, Branjerdporn G, Khan S, Hii Q, Keller S, Bartlett SE. A Systematic Review and Narrative Synthesis of Cognitive Training in the Treatment of Mental Illness and Substance Use Disorder. J Clin Med 2024; 13:4348. [PMID: 39124616 PMCID: PMC11312778 DOI: 10.3390/jcm13154348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2024] [Revised: 07/17/2024] [Accepted: 07/24/2024] [Indexed: 08/12/2024] Open
Abstract
Introduction: The one unifying and distinguishing feature of all neuropsychiatric illnesses is the co-occurrence of cognitive dysfunction. Cognitive training (CT) was developed to enhance neural connectivity and cognition and improve day-to-day functioning. However, the benefits of CT are still debated. This current systematic review aimed to examine the efficacy of CT and to identify diagnostic and CT characteristics associated with superior outcomes across a range of psychiatric disorders. Method: Studies investigating CT in psychiatric illnesses were extracted from Embase, PubMed, CINAHL, PsycINFO, and PsycARTICLES up to 17 August 2023. Inclusion criteria were randomised control trials (RCT) and English language. The primary search strategy included terms relating to cognitive training, cognitive remediation, cognitive enhancement, or cognitive rehabilitation and randomised control trials, clinical trials, or experiments. Risk of bias was assessed using RevMan Web version 8.1.1. Narrative synthesis was used to analyse findings. Due to the heterogeneity of participant demographics, diagnoses, and interventions, meta-analyses were considered inappropriate. Results: Fifteen studies, including a total of 1075 participants, were identified. Approximately 67% of studies reported significant improvements in at least one trained domain of cognitive function after CT, and 47% observed improvements in psychiatric symptoms or function. Cognitive transfer effects were not observed. Sample sizes for studies were generally small, and most CT durations were 6 weeks or less. Conclusions: Findings suggest that CT can improve cognitive function in trained domains, though little evidence of cognitive transfer effects was observed. Due to the lack of standardisation in CT format and delivery, and inadequate measures of psychiatric symptoms or daily function, there is insufficient evidence to conclude whether or not this technique may benefit cognitive impairment in psychiatric disorders, or lead to subsequent improvement in disease symptomatology. Further studies of longer duration and using consistent methodologies must be conducted to identify the benefits of CT in psychiatric disorders.
Collapse
Affiliation(s)
- Kerri M. Gillespie
- School of Clinical Sciences, Translational Research Institute, Faculty of Health, Queensland University of Technology, Kelvin Grove, QLD 4059, Australia;
| | - Alexander H. Dymond
- Gold Coast Hospital and Health Service, Southport, QLD 4215, Australia; (A.H.D.); (S.K.)
| | - Xin Li
- Mater Hospital, South Brisbane, QLD 4101, Australia; (X.L.); (D.S.); (G.B.)
| | - Daniel Schweitzer
- Mater Hospital, South Brisbane, QLD 4101, Australia; (X.L.); (D.S.); (G.B.)
| | - Grace Branjerdporn
- Mater Hospital, South Brisbane, QLD 4101, Australia; (X.L.); (D.S.); (G.B.)
| | - Saleha Khan
- Gold Coast Hospital and Health Service, Southport, QLD 4215, Australia; (A.H.D.); (S.K.)
| | - Quang Hii
- Forensic and Secure Services, The Park—Centre for Mental Health, Wacol, QLD 4076, Australia; (Q.H.); (S.K.)
| | - Suzie Keller
- Forensic and Secure Services, The Park—Centre for Mental Health, Wacol, QLD 4076, Australia; (Q.H.); (S.K.)
| | - Selena E. Bartlett
- School of Clinical Sciences, Translational Research Institute, Faculty of Health, Queensland University of Technology, Kelvin Grove, QLD 4059, Australia;
| |
Collapse
|
36
|
Lai LC, Huang DM, Peng J, Cao XY, Feng XL, Tao PY, Pan X, Pan QN, Fan DJ, Lu SY, Li CL, Pan YF, Dong PX, Chai YD, Huang P, Wu HC, Huang HQ. Depressive symptom mediates the association between the number of chronic diseases and cognitive impairment: a multi-center cross-sectional study based on community older adults. Front Psychiatry 2024; 15:1404229. [PMID: 39086730 PMCID: PMC11288913 DOI: 10.3389/fpsyt.2024.1404229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2024] [Accepted: 06/27/2024] [Indexed: 08/02/2024] Open
Abstract
Objective The purpose of this study was to understand the relationship between the multiple chronic conditions (MCC), mental health and cognitive function of older adults in the community, and to propose a hypothesis that depressive symptom mediate the number of chronic diseases and cognitive impairment in older adults. Method Participants aged 65 years and older from 35 communities in 14 cities in Guangxi, China were recruited. The residents' depressive symptom (PHQ-9) and cognitive status (AD-8) were evaluated, Chi-square test was used to explore the effects of different socio-demographic characteristics on depressive symptom and cognitive impairment. Pearson correlation analysis and the process model 4 were used to explore the relationship between the number of chronic diseases, depressive symptom and cognitive impairment. Result A total of 11,582 older adults were included in our analysis. The rate of MCC reaching 26.53%. Hypertension combined with diabetes accounts for the highest proportion of two chronic diseases (13.2%). Among the combination of three chronic diseases, the highest incidence of coexisting hypertension combined with cervical/lumbar spondylosis, and rheumatoid arthritis (7.1%). In this study, depression symptoms accounted for 12.9% of older adults aged 65 and above, and cognitive impairment accounted for 27.4%. Female, older age, reside in urban areas, lower educational levels, no spouse, live alone, and MCC were risk factors for depressive symptom and cognitive impairment in older adults (P<0.05). Depressive symptom had a mediating effect in the number of chronic diseases and cognitive impairment, and the mediating effect (1.109) accounted for 44.13% of the total effect (0.247). Conclusion The mental health of the older adult needs to be taken seriously, and improving depressive symptom can reduce the occurrence of cognitive impairment in older patients with MCC to a certain extent.
Collapse
Affiliation(s)
- Li-Chong Lai
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Dong-Mei Huang
- Rehabilitation Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Jie Peng
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Xiao-Ying Cao
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Xiao-Ling Feng
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Pin-Yue Tao
- Anesthesiology Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Xiao Pan
- Ear, Nose, Throat, Head and Neck Surgery, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Qi-Ni Pan
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Deng-Jing Fan
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Shu-Yu Lu
- Anesthesiology Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Cai-Li Li
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Yan-Fei Pan
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Peng-Xin Dong
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Yi-Dan Chai
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Ping- Huang
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Hai-Chen Wu
- Nursing Department, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| | - Hui-Qiao Huang
- Party Committee Office, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
| |
Collapse
|
37
|
Li D, Li X, Li J, Liu J, Luo R, Li Y, Wang D, Zhou D, Zhang XY. Neurophysiological markers of disease severity and cognitive dysfunction in major depressive disorder: A TMS-EEG study. Int J Clin Health Psychol 2024; 24:100495. [PMID: 39282218 PMCID: PMC11402404 DOI: 10.1016/j.ijchp.2024.100495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Accepted: 08/12/2024] [Indexed: 09/18/2024] Open
Abstract
Background Transcranial magnetic stimulation-electroencephalography (TMS-EEG) is a powerful technique to study the neuropathology and biomarkers of major depressive disorder (MDD). This study investigated cortical activity and its relationship with clinical symptoms and cognitive dysfunction in MDD patients by indexing TMS-EEG biomarkers in the dorsolateral prefrontal cortex (DLPFC). Methods 133 patients with MDD and 76 healthy individuals participated in this study. Single-pulse TMS was performed on the left DLPFC to obtain TMS-evoked potential (TEP) indices. TMS-EEG waveforms and components were determined by global mean field amplitude. We used the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to measure participants' cognitive function. Results Patients with MDD had a lower excitatory P180 index compared to healthy controls, and P180 amplitude was negatively correlated with the severity of depressive and anxiety symptoms in patients with MDD. In the MDD group, P30 amplitude was negatively associated with RBANS Visuospatial/ Constructional index and total score. Conclusions TMS-EEG findings suggest that abnormal cortical excitation and inhibition induced by TMS on the DLPFC are associated with the severity of clinical symptoms and cognitive dysfunction in patients with MDD. P180 and P30 have the potential to serve as neurophysiological biomarkers of clinical symptoms and cognitive dysfunction in MDD patients, respectively.
Collapse
Affiliation(s)
- Deyang Li
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Xingxing Li
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
- Department of psychiatry, Affiliated Kangning Hospital of Ningbo University, Ningbo, Zhejiang, China
- Department of psychiatry, Ningbo Kangning Hospital, Ningbo, Zhejiang, China
| | - Jiaxin Li
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Junyao Liu
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Ruichenxi Luo
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Yanli Li
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Dongmei Wang
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| | - Dongsheng Zhou
- Department of psychiatry, Affiliated Kangning Hospital of Ningbo University, Ningbo, Zhejiang, China
- Department of psychiatry, Ningbo Kangning Hospital, Ningbo, Zhejiang, China
| | - Xiang-Yang Zhang
- CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China
- Department of Psychology, University of Chinese Academy of Sciences, Beijing, China
| |
Collapse
|
38
|
Kennedy E, Liebel SW, Lindsey HM, Vadlamani S, Lei PW, Adamson MM, Alda M, Alonso-Lana S, Anderson TJ, Arango C, Asarnow RF, Avram M, Ayesa-Arriola R, Babikian T, Banaj N, Bird LJ, Borgwardt S, Brodtmann A, Brosch K, Caeyenberghs K, Calhoun VD, Chiaravalloti ND, Cifu DX, Crespo-Facorro B, Dalrymple-Alford JC, Dams-O’Connor K, Dannlowski U, Darby D, Davenport N, DeLuca J, Diaz-Caneja CM, Disner SG, Dobryakova E, Ehrlich S, Esopenko C, Ferrarelli F, Frank LE, Franz CE, Fuentes-Claramonte P, Genova H, Giza CC, Goltermann J, Grotegerd D, Gruber M, Gutierrez-Zotes A, Ha M, Haavik J, Hinkin C, Hoskinson KR, Hubl D, Irimia A, Jansen A, Kaess M, Kang X, Kenney K, Keřková B, Khlif MS, Kim M, Kindler J, Kircher T, Knížková K, Kolskår KK, Krch D, Kremen WS, Kuhn T, Kumari V, Kwon J, Langella R, Laskowitz S, Lee J, Lengenfelder J, Liou-Johnson V, Lippa SM, Løvstad M, Lundervold AJ, Marotta C, Marquardt CA, Mattos P, Mayeli A, McDonald CR, Meinert S, Melzer TR, Merchán-Naranjo J, Michel C, Morey RA, Mwangi B, Myall DJ, Nenadić I, Newsome MR, Nunes A, O’Brien T, Oertel V, Ollinger J, Olsen A, Ortiz García de la Foz V, Ozmen M, Pardoe H, Parent M, Piras F, Piras F, et alKennedy E, Liebel SW, Lindsey HM, Vadlamani S, Lei PW, Adamson MM, Alda M, Alonso-Lana S, Anderson TJ, Arango C, Asarnow RF, Avram M, Ayesa-Arriola R, Babikian T, Banaj N, Bird LJ, Borgwardt S, Brodtmann A, Brosch K, Caeyenberghs K, Calhoun VD, Chiaravalloti ND, Cifu DX, Crespo-Facorro B, Dalrymple-Alford JC, Dams-O’Connor K, Dannlowski U, Darby D, Davenport N, DeLuca J, Diaz-Caneja CM, Disner SG, Dobryakova E, Ehrlich S, Esopenko C, Ferrarelli F, Frank LE, Franz CE, Fuentes-Claramonte P, Genova H, Giza CC, Goltermann J, Grotegerd D, Gruber M, Gutierrez-Zotes A, Ha M, Haavik J, Hinkin C, Hoskinson KR, Hubl D, Irimia A, Jansen A, Kaess M, Kang X, Kenney K, Keřková B, Khlif MS, Kim M, Kindler J, Kircher T, Knížková K, Kolskår KK, Krch D, Kremen WS, Kuhn T, Kumari V, Kwon J, Langella R, Laskowitz S, Lee J, Lengenfelder J, Liou-Johnson V, Lippa SM, Løvstad M, Lundervold AJ, Marotta C, Marquardt CA, Mattos P, Mayeli A, McDonald CR, Meinert S, Melzer TR, Merchán-Naranjo J, Michel C, Morey RA, Mwangi B, Myall DJ, Nenadić I, Newsome MR, Nunes A, O’Brien T, Oertel V, Ollinger J, Olsen A, Ortiz García de la Foz V, Ozmen M, Pardoe H, Parent M, Piras F, Piras F, Pomarol-Clotet E, Repple J, Richard G, Rodriguez J, Rodriguez M, Rootes-Murdy K, Rowland J, Ryan NP, Salvador R, Sanders AM, Schmidt A, Soares JC, Spalleta G, Španiel F, Sponheim SR, Stasenko A, Stein F, Straube B, Thames A, Thomas-Odenthal F, Thomopoulos SI, Tone EB, Torres I, Troyanskaya M, Turner JA, Ulrichsen KM, Umpierrez G, Vecchio D, Vilella E, Vivash L, Walker WC, Werden E, Westlye LT, Wild K, Wroblewski A, Wu MJ, Wylie GR, Yatham LN, Zunta-Soares GB, Thompson PM, Pugh MJ, Tate DF, Hillary FG, Wilde EA, Dennis EL. Verbal Learning and Memory Deficits across Neurological and Neuropsychiatric Disorders: Insights from an ENIGMA Mega Analysis. Brain Sci 2024; 14:669. [PMID: 39061410 PMCID: PMC11274572 DOI: 10.3390/brainsci14070669] [Show More Authors] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2024] [Revised: 06/20/2024] [Accepted: 06/26/2024] [Indexed: 07/28/2024] Open
Abstract
Deficits in memory performance have been linked to a wide range of neurological and neuropsychiatric conditions. While many studies have assessed the memory impacts of individual conditions, this study considers a broader perspective by evaluating how memory recall is differentially associated with nine common neuropsychiatric conditions using data drawn from 55 international studies, aggregating 15,883 unique participants aged 15-90. The effects of dementia, mild cognitive impairment, Parkinson's disease, traumatic brain injury, stroke, depression, attention-deficit/hyperactivity disorder (ADHD), schizophrenia, and bipolar disorder on immediate, short-, and long-delay verbal learning and memory (VLM) scores were estimated relative to matched healthy individuals. Random forest models identified age, years of education, and site as important VLM covariates. A Bayesian harmonization approach was used to isolate and remove site effects. Regression estimated the adjusted association of each clinical group with VLM scores. Memory deficits were strongly associated with dementia and schizophrenia (p < 0.001), while neither depression nor ADHD showed consistent associations with VLM scores (p > 0.05). Differences associated with clinical conditions were larger for longer delayed recall duration items. By comparing VLM across clinical conditions, this study provides a foundation for enhanced diagnostic precision and offers new insights into disease management of comorbid disorders.
Collapse
Affiliation(s)
- Eamonn Kennedy
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
- Division of Epidemiology, University of Utah, Salt Lake City, UT 84108, USA;
- George E Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA
| | - Spencer W. Liebel
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
- George E Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA
| | - Hannah M. Lindsey
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
- George E Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA
| | - Shashank Vadlamani
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
| | - Pui-Wa Lei
- Department of Educational Psychology, Counseling, and Special Education, Pennsylvania State University, University Park, PA 16802, USA;
| | - Maheen M. Adamson
- WRIISC-WOMEN & Rehabilitation Department, VA Palo Alto, Palo Alto, CA 94304, USA (X.K.); (V.L.-J.)
- Neurosurgery, Stanford School of Medicine, Stanford, CA 94305, USA
| | - Martin Alda
- Department of Psychiatry, Dalhousie University, Halifax, NS B3H 4R2, Canada; (M.A.); (A.N.)
| | - Silvia Alonso-Lana
- FIDMAG Research Foundation, 08025 Barcelona, Spain; (S.A.-L.); (P.F.-C.); (E.P.-C.); (R.S.)
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
- Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya, 08022 Barcelona, Spain
| | - Tim J. Anderson
- Department of Medicine, University of Otago, Christchurch 8011, New Zealand; (T.J.A.); (J.C.D.-A.); (T.R.M.)
- New Zealand Brain Research Institute, Christchurch 8011, New Zealand;
- Department of Neurology, Te Whatu Ora–Health New Zealand Waitaha Canterbury, Christchurch 8011, New Zealand
| | - Celso Arango
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
- Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), School of Medicine, Universidad Complutense, 28040 Madrid, Spain; (C.M.D.-C.); (J.M.-N.)
| | - Robert F. Asarnow
- Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA 90095, USA; (R.F.A.); (T.B.); (C.H.); (T.K.); (A.T.)
- Brain Research Institute, University of California Los Angeles, Los Angeles, CA 90095, USA
- Department of Psychology, University of California Los Angeles, Los Angeles, CA 90095, USA
| | - Mihai Avram
- Translational Psychiatry, Department of Psychiatry and Psychotherapy, University of Lübeck, 23562 Lübeck, Germany; (M.A.); (S.B.)
| | - Rosa Ayesa-Arriola
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
- Department of Psychiatry, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), School of Medicine, University of Cantabria, 39008 Santander, Spain;
| | - Talin Babikian
- Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA 90095, USA; (R.F.A.); (T.B.); (C.H.); (T.K.); (A.T.)
- UCLA Steve Tisch BrainSPORT Program, University of California Los Angeles, Los Angeles, CA 90095, USA;
| | - Nerisa Banaj
- Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, 00179 Rome, Italy; (N.B.); (R.L.); (F.P.); (F.P.); (G.S.); (D.V.)
| | - Laura J. Bird
- School of Clinical Sciences, Monash University, Clayton, VIC 3800, Australia;
| | - Stefan Borgwardt
- Translational Psychiatry, Department of Psychiatry and Psychotherapy, University of Lübeck, 23562 Lübeck, Germany; (M.A.); (S.B.)
- Center of Brain, Behaviour and Metabolism (CBBM), University of Lübeck, 23562 Lübeck, Germany
| | - Amy Brodtmann
- Cognitive Health Initiative, School of Translational Medicine, Monash University, Melbourne, VIC 3800, Australia;
- Department of Medicine, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia;
| | - Katharina Brosch
- Department of Psychiatry and Psychotherapy, University of Marburg, 35032 Marburg, Germany; (K.B.); (A.J.); (T.K.); (I.N.); (F.S.); (B.S.); (F.T.-O.); (A.W.)
- Institute of Behavioral Science, Feinstein Institutes for Medical Research, Manhasset, NY 11030, USA
| | - Karen Caeyenberghs
- Cognitive Neuroscience Unit, School of Psychology, Deakin University, Burwood, VIC 3125, Australia;
| | - Vince D. Calhoun
- Tri-Institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State, Georgia Tech, Emory University, Atlanta, GA 30322, USA; (V.D.C.); (K.R.-M.)
| | - Nancy D. Chiaravalloti
- Centers for Neuropsychology, Neuroscience & Traumatic Brain Injury Research, Kessler Foundation, East Hanover, NJ 07936, USA;
- Department of Physical Medicine & Rehabilitation, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA; (J.D.); (E.D.); (H.G.); (D.K.); (J.L.); (G.R.W.)
| | - David X. Cifu
- Rehabilitation Medicine Department, National Institutes of Health Clinical Center, Bethesda, MD 20892, USA;
| | - Benedicto Crespo-Facorro
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
- Department of Psychiatry, Virgen del Rocio University Hospital, School of Medicine, University of Seville, IBIS, 41013 Seville, Spain
| | - John C. Dalrymple-Alford
- Department of Medicine, University of Otago, Christchurch 8011, New Zealand; (T.J.A.); (J.C.D.-A.); (T.R.M.)
- New Zealand Brain Research Institute, Christchurch 8011, New Zealand;
- School of Psychology, Speech and Hearing, University of Canterbury, Christchurch 8041, New Zealand
| | - Kristen Dams-O’Connor
- Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA (C.E.)
- Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Udo Dannlowski
- Institute for Translational Psychiatry, University of Münster, 48149 Münster, Germany; (U.D.); (J.G.); (D.G.); (M.G.); (S.M.); (J.R.)
| | - David Darby
- Department of Neuroscience, Monash University, Melbourne, VIC 3800, Australia; (D.D.); (C.M.); (L.V.)
- Department of Neurology, Alfred Health, Melbourne, VIC 3004, Australia
- The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC 3052, Australia; (H.P.); (E.W.)
| | - Nicholas Davenport
- Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, MN 55455, USA; (N.D.); (S.G.D.); (C.A.M.); (S.R.S.)
- Minneapolis VA Health Care System, Minneapolis, MN 55417, USA
| | - John DeLuca
- Department of Physical Medicine & Rehabilitation, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA; (J.D.); (E.D.); (H.G.); (D.K.); (J.L.); (G.R.W.)
- Kessler Foundation, East Hanover, NJ 07936, USA
| | - Covadonga M. Diaz-Caneja
- Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), School of Medicine, Universidad Complutense, 28040 Madrid, Spain; (C.M.D.-C.); (J.M.-N.)
| | - Seth G. Disner
- Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, MN 55455, USA; (N.D.); (S.G.D.); (C.A.M.); (S.R.S.)
- Minneapolis VA Health Care System, Minneapolis, MN 55417, USA
| | - Ekaterina Dobryakova
- Department of Physical Medicine & Rehabilitation, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA; (J.D.); (E.D.); (H.G.); (D.K.); (J.L.); (G.R.W.)
- Center for Traumatic Brain Injury, Kessler Foundation, East Hanover, NJ 07936, USA
| | - Stefan Ehrlich
- Translational Developmental Neuroscience Section, Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, 01307 Dresden, Germany;
- Eating Disorders Research and Treatment Center, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, 01307 Dresden, Germany
| | - Carrie Esopenko
- Department of Rehabilitation and Human Performance, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA (C.E.)
| | - Fabio Ferrarelli
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA; (F.F.); (A.M.)
| | - Lea E. Frank
- Department of Psychology, University of Oregon, Eugene, OR 97403, USA
| | - Carol E. Franz
- Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA; (C.E.F.); (W.S.K.); (J.R.); (A.S.)
- Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA 92093, USA
| | - Paola Fuentes-Claramonte
- FIDMAG Research Foundation, 08025 Barcelona, Spain; (S.A.-L.); (P.F.-C.); (E.P.-C.); (R.S.)
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
| | - Helen Genova
- Department of Physical Medicine & Rehabilitation, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA; (J.D.); (E.D.); (H.G.); (D.K.); (J.L.); (G.R.W.)
- Center for Autism Research, Kessler Foundation, East Hanover, NJ 07936, USA
| | - Christopher C. Giza
- UCLA Steve Tisch BrainSPORT Program, University of California Los Angeles, Los Angeles, CA 90095, USA;
- Department of Pediatrics, Division of Neurology, UCLA Mattel Children’s Hospital, Los Angeles, CA 90095, USA
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
| | - Janik Goltermann
- Institute for Translational Psychiatry, University of Münster, 48149 Münster, Germany; (U.D.); (J.G.); (D.G.); (M.G.); (S.M.); (J.R.)
| | - Dominik Grotegerd
- Institute for Translational Psychiatry, University of Münster, 48149 Münster, Germany; (U.D.); (J.G.); (D.G.); (M.G.); (S.M.); (J.R.)
| | - Marius Gruber
- Institute for Translational Psychiatry, University of Münster, 48149 Münster, Germany; (U.D.); (J.G.); (D.G.); (M.G.); (S.M.); (J.R.)
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany
| | - Alfonso Gutierrez-Zotes
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
- Hospital Universitari Institut Pere Mata, 43007 Tarragona, Spain
- Institut d’Investiació Sanitària Pere Virgili-CERCA, Universitat Rovira i Virgili, 43007 Tarragona, Spain
| | - Minji Ha
- Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul 08826, Republic of Korea; (M.H.); (J.K.); (J.L.)
| | - Jan Haavik
- Department of Biomedicine, University of Bergen, 5007 Bergen, Norway;
- Division of Psychiatry, Haukeland University Hospital, 5021 Bergen, Norway
| | - Charles Hinkin
- Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA 90095, USA; (R.F.A.); (T.B.); (C.H.); (T.K.); (A.T.)
| | - Kristen R. Hoskinson
- Center for Biobehavioral Health, The Abigail Wexner Research Institute at Nationwide Children’s Hospital, Columbus, OH 43205, USA;
- Section of Pediatrics, The Ohio State University College of Medicine, Columbus, OH 43210, USA
| | - Daniela Hubl
- Translational Research Centre, University Hospital of Psychiatry and Psychotherapy, University of Bern, 3000 Bern, Switzerland;
| | - Andrei Irimia
- Ethel Percy Andrus Gerontology Center, Leonard Davis School of Gerontology, University of Southern California, Los Angeles, CA 90089, USA;
- Department of Biomedical Engineering, Viterbi School of Engineering, University of Southern California, Los Angeles, CA 90089, USA
- Department of Quantitative & Computational Biology, Dornsife College of Arts & Sciences, University of Southern California, Los Angeles, CA 90089, USA
| | - Andreas Jansen
- Department of Psychiatry and Psychotherapy, University of Marburg, 35032 Marburg, Germany; (K.B.); (A.J.); (T.K.); (I.N.); (F.S.); (B.S.); (F.T.-O.); (A.W.)
| | - Michael Kaess
- University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, 3000 Bern, Switzerland; (M.K.); (J.K.); (C.M.)
- Clinic of Child and Adolescent Psychiatry, Centre of Psychosocial Medicine, University of Heidelberg, 69120 Heidelberg, Germany
| | - Xiaojian Kang
- WRIISC-WOMEN & Rehabilitation Department, VA Palo Alto, Palo Alto, CA 94304, USA (X.K.); (V.L.-J.)
| | - Kimbra Kenney
- Department of Neurology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA;
| | - Barbora Keřková
- National Institute of Mental Health, 250 67 Klecany, Czech Republic; (B.K.); (K.K.); (M.R.); (F.Š.)
| | - Mohamed Salah Khlif
- Cognitive Health Initiative, Central Clinical School, Monash University, Melbourne, VIC 3800, Australia;
| | - Minah Kim
- Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03080, Republic of Korea;
- Department of Psychiatry, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Jochen Kindler
- University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, 3000 Bern, Switzerland; (M.K.); (J.K.); (C.M.)
| | - Tilo Kircher
- Department of Psychiatry and Psychotherapy, University of Marburg, 35032 Marburg, Germany; (K.B.); (A.J.); (T.K.); (I.N.); (F.S.); (B.S.); (F.T.-O.); (A.W.)
| | - Karolina Knížková
- National Institute of Mental Health, 250 67 Klecany, Czech Republic; (B.K.); (K.K.); (M.R.); (F.Š.)
- Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital, 128 00 Prague, Czech Republic
| | - Knut K. Kolskår
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, 0424 Oslo, Norway; (K.K.K.); (G.R.); (A.-M.S.); (K.M.U.); (L.T.W.)
- Department of Psychology, University of Oslo, 0373 Oslo, Norway;
- Department of Research, Sunnaas Rehabilitation Hospital, 1450 Nesodden, Norway
| | - Denise Krch
- Department of Physical Medicine & Rehabilitation, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA; (J.D.); (E.D.); (H.G.); (D.K.); (J.L.); (G.R.W.)
- Center for Traumatic Brain Injury, Kessler Foundation, East Hanover, NJ 07936, USA
| | - William S. Kremen
- Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA; (C.E.F.); (W.S.K.); (J.R.); (A.S.)
- Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA 92093, USA
| | - Taylor Kuhn
- Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA 90095, USA; (R.F.A.); (T.B.); (C.H.); (T.K.); (A.T.)
| | - Veena Kumari
- Department of Life Sciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK;
| | - Junsoo Kwon
- Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul 08826, Republic of Korea; (M.H.); (J.K.); (J.L.)
- Department of Neuropsychiatry, Seoul National University Hospital, Seoul 03080, Republic of Korea;
- Department of Psychiatry, Seoul National University College of Medicine, Seoul 03080, Republic of Korea
| | - Roberto Langella
- Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, 00179 Rome, Italy; (N.B.); (R.L.); (F.P.); (F.P.); (G.S.); (D.V.)
| | - Sarah Laskowitz
- Brain Imaging and Analysis Center, Duke University, Durham, NC 27710, USA; (S.L.); (R.A.M.)
| | - Jungha Lee
- Department of Brain and Cognitive Sciences, Seoul National University College of Natural Sciences, Seoul 08826, Republic of Korea; (M.H.); (J.K.); (J.L.)
| | - Jean Lengenfelder
- Department of Physical Medicine & Rehabilitation, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA; (J.D.); (E.D.); (H.G.); (D.K.); (J.L.); (G.R.W.)
- Center for Traumatic Brain Injury, Kessler Foundation, East Hanover, NJ 07936, USA
| | - Victoria Liou-Johnson
- WRIISC-WOMEN & Rehabilitation Department, VA Palo Alto, Palo Alto, CA 94304, USA (X.K.); (V.L.-J.)
| | - Sara M. Lippa
- National Intrepid Center of Excellence, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA; (S.M.L.); (J.O.)
- Department of Neuroscience, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
| | - Marianne Løvstad
- Department of Psychology, University of Oslo, 0373 Oslo, Norway;
- Department of Research, Sunnaas Rehabilitation Hospital, 1450 Nesodden, Norway
| | - Astri J. Lundervold
- Department of Biological and Medical Psychology, University of Bergen, 5007 Bergen, Norway;
| | - Cassandra Marotta
- Department of Neuroscience, Monash University, Melbourne, VIC 3800, Australia; (D.D.); (C.M.); (L.V.)
- Department of Neurology, Alfred Health, Melbourne, VIC 3004, Australia
| | - Craig A. Marquardt
- Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, MN 55455, USA; (N.D.); (S.G.D.); (C.A.M.); (S.R.S.)
- Minneapolis VA Health Care System, Minneapolis, MN 55417, USA
| | - Paulo Mattos
- Institute D’Or for Research and Education (IDOR), São Paulo 04501-000, Brazil;
| | - Ahmad Mayeli
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15213, USA; (F.F.); (A.M.)
| | - Carrie R. McDonald
- Department of Radiation Medicine and Applied Sciences and Psychiatry, University of California San Diego, La Jolla, CA 92093, USA;
- Center for Multimodal Imaging and Genetics, University of California San Diego, La Jolla, CA 92093, USA
| | - Susanne Meinert
- Institute for Translational Psychiatry, University of Münster, 48149 Münster, Germany; (U.D.); (J.G.); (D.G.); (M.G.); (S.M.); (J.R.)
- Institute for Translational Neuroscience, University of Münster, 48149 Münster, Germany
| | - Tracy R. Melzer
- Department of Medicine, University of Otago, Christchurch 8011, New Zealand; (T.J.A.); (J.C.D.-A.); (T.R.M.)
- New Zealand Brain Research Institute, Christchurch 8011, New Zealand;
- School of Psychology, Speech and Hearing, University of Canterbury, Christchurch 8041, New Zealand
| | - Jessica Merchán-Naranjo
- Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), School of Medicine, Universidad Complutense, 28040 Madrid, Spain; (C.M.D.-C.); (J.M.-N.)
| | - Chantal Michel
- University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, 3000 Bern, Switzerland; (M.K.); (J.K.); (C.M.)
| | - Rajendra A. Morey
- Brain Imaging and Analysis Center, Duke University, Durham, NC 27710, USA; (S.L.); (R.A.M.)
- VISN 6 MIRECC, Durham VA, Durham, NC 27705, USA
| | - Benson Mwangi
- Center of Excellence on Mood Disorders, Louis A Faillace, MD Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; (B.M.); (J.C.S.); (M.-J.W.); (G.B.Z.-S.)
| | - Daniel J. Myall
- New Zealand Brain Research Institute, Christchurch 8011, New Zealand;
| | - Igor Nenadić
- Department of Psychiatry and Psychotherapy, University of Marburg, 35032 Marburg, Germany; (K.B.); (A.J.); (T.K.); (I.N.); (F.S.); (B.S.); (F.T.-O.); (A.W.)
| | - Mary R. Newsome
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
- George E Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA
| | - Abraham Nunes
- Department of Psychiatry, Dalhousie University, Halifax, NS B3H 4R2, Canada; (M.A.); (A.N.)
- Faculty of Computer Science, Dalhousie University, Halifax, NS B3H 4R2, Canada
| | - Terence O’Brien
- Department of Medicine, Royal Melbourne Hospital, Melbourne, VIC 3050, Australia;
- Department of Neuroscience, The School of Translational Medicine, Alfred Health, Monash University, Melbourne VIC 3004, Australia
| | - Viola Oertel
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Frankfurt University, 60590 Frankfurt, Germany;
| | - John Ollinger
- National Intrepid Center of Excellence, Walter Reed National Military Medical Center, Bethesda, MD 20814, USA; (S.M.L.); (J.O.)
| | - Alexander Olsen
- Department of Psychology, Norwegian University of Science and Technology, 7491 Trondheim, Norway;
- Department of Physical Medicine and Rehabilitation, St Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway
- NorHEAD—Norwegian Centre for Headache Research, 7491 Trondheim, Norway
| | - Victor Ortiz García de la Foz
- Department of Psychiatry, Marqués de Valdecilla University Hospital, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), School of Medicine, University of Cantabria, 39008 Santander, Spain;
| | - Mustafa Ozmen
- Division of Epidemiology, University of Utah, Salt Lake City, UT 84108, USA;
- Department of Electrical and Electronics Engineering, Antalya Bilim University, 07190 Antalya, Turkey
| | - Heath Pardoe
- The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC 3052, Australia; (H.P.); (E.W.)
| | - Marise Parent
- Neuroscience Institute & Department of Psychology, Georgia State University, Atlanta, GA 30303, USA;
| | - Fabrizio Piras
- Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, 00179 Rome, Italy; (N.B.); (R.L.); (F.P.); (F.P.); (G.S.); (D.V.)
| | - Federica Piras
- Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, 00179 Rome, Italy; (N.B.); (R.L.); (F.P.); (F.P.); (G.S.); (D.V.)
| | - Edith Pomarol-Clotet
- FIDMAG Research Foundation, 08025 Barcelona, Spain; (S.A.-L.); (P.F.-C.); (E.P.-C.); (R.S.)
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
| | - Jonathan Repple
- Institute for Translational Psychiatry, University of Münster, 48149 Münster, Germany; (U.D.); (J.G.); (D.G.); (M.G.); (S.M.); (J.R.)
- Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Goethe University, 60590 Frankfurt, Germany
| | - Geneviève Richard
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, 0424 Oslo, Norway; (K.K.K.); (G.R.); (A.-M.S.); (K.M.U.); (L.T.W.)
| | - Jonathan Rodriguez
- Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA; (C.E.F.); (W.S.K.); (J.R.); (A.S.)
| | - Mabel Rodriguez
- National Institute of Mental Health, 250 67 Klecany, Czech Republic; (B.K.); (K.K.); (M.R.); (F.Š.)
| | - Kelly Rootes-Murdy
- Tri-Institutional Center for Translational Research in Neuroimaging and Data Science (TReNDS), Georgia State, Georgia Tech, Emory University, Atlanta, GA 30322, USA; (V.D.C.); (K.R.-M.)
| | - Jared Rowland
- WG (Bill) Hefner VA Medical Center, Salisbury, NC 28144, USA;
- Department of Neurobiology & Anatomy, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
- VA Mid-Atlantic Mental Illness Research Education and Clinical Center (MA-MIRECC), Durham, NC 27705, USA
| | - Nicholas P. Ryan
- Cognitive Neuroscience Unit, School of Psychology, Deakin University, Geelong, VIC 3220, Australia;
- Department of Paediatrics, The University of Melbourne, Parkville, VIC 3052, Australia
| | - Raymond Salvador
- FIDMAG Research Foundation, 08025 Barcelona, Spain; (S.A.-L.); (P.F.-C.); (E.P.-C.); (R.S.)
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
| | - Anne-Marthe Sanders
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, 0424 Oslo, Norway; (K.K.K.); (G.R.); (A.-M.S.); (K.M.U.); (L.T.W.)
- Department of Psychology, University of Oslo, 0373 Oslo, Norway;
- Department of Research, Sunnaas Rehabilitation Hospital, 1450 Nesodden, Norway
| | - Andre Schmidt
- Department of Psychiatry (UPK), University of Basel, 4002 Basel, Switzerland;
| | - Jair C. Soares
- Center of Excellence on Mood Disorders, Louis A Faillace, MD Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; (B.M.); (J.C.S.); (M.-J.W.); (G.B.Z.-S.)
| | - Gianfranco Spalleta
- Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, 00179 Rome, Italy; (N.B.); (R.L.); (F.P.); (F.P.); (G.S.); (D.V.)
| | - Filip Španiel
- National Institute of Mental Health, 250 67 Klecany, Czech Republic; (B.K.); (K.K.); (M.R.); (F.Š.)
- 3rd Faculty of Medicine, Charles University, 100 00 Prague, Czech Republic
| | - Scott R. Sponheim
- Department of Psychiatry and Behavioral Sciences, University of Minnesota Medical School, Minneapolis, MN 55455, USA; (N.D.); (S.G.D.); (C.A.M.); (S.R.S.)
- Minneapolis VA Health Care System, Minneapolis, MN 55417, USA
| | - Alena Stasenko
- Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA; (C.E.F.); (W.S.K.); (J.R.); (A.S.)
- Center for Multimodal Imaging and Genetics, University of California San Diego, La Jolla, CA 92093, USA
| | - Frederike Stein
- Department of Psychiatry and Psychotherapy, University of Marburg, 35032 Marburg, Germany; (K.B.); (A.J.); (T.K.); (I.N.); (F.S.); (B.S.); (F.T.-O.); (A.W.)
| | - Benjamin Straube
- Department of Psychiatry and Psychotherapy, University of Marburg, 35032 Marburg, Germany; (K.B.); (A.J.); (T.K.); (I.N.); (F.S.); (B.S.); (F.T.-O.); (A.W.)
| | - April Thames
- Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, CA 90095, USA; (R.F.A.); (T.B.); (C.H.); (T.K.); (A.T.)
| | - Florian Thomas-Odenthal
- Department of Psychiatry and Psychotherapy, University of Marburg, 35032 Marburg, Germany; (K.B.); (A.J.); (T.K.); (I.N.); (F.S.); (B.S.); (F.T.-O.); (A.W.)
| | - Sophia I. Thomopoulos
- Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA 90292, USA; (S.I.T.); (P.M.T.)
| | - Erin B. Tone
- Department of Psychology, Georgia State University, Atlanta, GA 30303, USA;
| | - Ivan Torres
- Department of Psychiatry, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; (I.T.); (L.N.Y.)
- British Columbia Mental Health and Substance Use Services Research Institute, Vancouver, BC V5Z 1M9, Canada
| | - Maya Troyanskaya
- Michael E DeBakey Veterans Affairs Medical Center, Houston, TX 77030, USA;
- H Ben Taub Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jessica A. Turner
- Psychiatry and Behavioral Health, Ohio State Wexner Medical Center, Columbus, OH 43210, USA;
| | - Kristine M. Ulrichsen
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, 0424 Oslo, Norway; (K.K.K.); (G.R.); (A.-M.S.); (K.M.U.); (L.T.W.)
- Department of Psychology, University of Oslo, 0373 Oslo, Norway;
- Department of Research, Sunnaas Rehabilitation Hospital, 1450 Nesodden, Norway
| | - Guillermo Umpierrez
- Division of Endocrinology, Emory University School of Medicine, Atlanta, GA 30322, USA;
| | - Daniela Vecchio
- Laboratory of Neuropsychiatry, Santa Lucia Foundation IRCCS, 00179 Rome, Italy; (N.B.); (R.L.); (F.P.); (F.P.); (G.S.); (D.V.)
| | - Elisabet Vilella
- Centro Investigación Biomédica en Red Salud Mental (CIBERSAM), 28029 Madrid, Spain; (C.A.); (R.A.-A.); (B.C.-F.); (A.G.-Z.); (E.V.)
- Hospital Universitari Institut Pere Mata, 43007 Tarragona, Spain
- Institut d’Investiació Sanitària Pere Virgili-CERCA, Universitat Rovira i Virgili, 43007 Tarragona, Spain
| | - Lucy Vivash
- Department of Neuroscience, Monash University, Melbourne, VIC 3800, Australia; (D.D.); (C.M.); (L.V.)
- Department of Neurology, Alfred Health, Melbourne, VIC 3004, Australia
| | - William C. Walker
- Department of Physical Medicine and Rehabilitation, Virginia Commonwealth University, Richmond, VA 23298, USA;
- Richmond Veterans Affairs (VA) Medical Center, Central Virginia VA Health Care System, Richmond, VA 23249, USA
| | - Emilio Werden
- The Florey Institute of Neuroscience and Mental Health, Melbourne, VIC 3052, Australia; (H.P.); (E.W.)
| | - Lars T. Westlye
- Norwegian Centre for Mental Disorders Research (NORMENT), Division of Mental Health and Addiction, Oslo University Hospital, 0424 Oslo, Norway; (K.K.K.); (G.R.); (A.-M.S.); (K.M.U.); (L.T.W.)
- Department of Psychology, University of Oslo, 0373 Oslo, Norway;
- KG Jebsen Center for Neurodevelopmental Disorders, University of Oslo, 0372 Oslo, Norway
| | - Krista Wild
- Department of Psychology, Phoenix VA Health Care System, Phoenix, AZ 85012, USA;
| | - Adrian Wroblewski
- Department of Psychiatry and Psychotherapy, University of Marburg, 35032 Marburg, Germany; (K.B.); (A.J.); (T.K.); (I.N.); (F.S.); (B.S.); (F.T.-O.); (A.W.)
| | - Mon-Ju Wu
- Center of Excellence on Mood Disorders, Louis A Faillace, MD Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; (B.M.); (J.C.S.); (M.-J.W.); (G.B.Z.-S.)
| | - Glenn R. Wylie
- Department of Physical Medicine & Rehabilitation, Rutgers, New Jersey Medical School, Newark, NJ 07103, USA; (J.D.); (E.D.); (H.G.); (D.K.); (J.L.); (G.R.W.)
- Rocco Ortenzio Neuroimaging Center, Kessler Foundation, East Hanover, NJ 07936, USA
| | - Lakshmi N. Yatham
- Department of Psychiatry, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; (I.T.); (L.N.Y.)
| | - Giovana B. Zunta-Soares
- Center of Excellence on Mood Disorders, Louis A Faillace, MD Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA; (B.M.); (J.C.S.); (M.-J.W.); (G.B.Z.-S.)
| | - Paul M. Thompson
- Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck School of Medicine of the University of Southern California, Marina del Rey, CA 90292, USA; (S.I.T.); (P.M.T.)
- Departments of Neurology, Pediatrics, Psychiatry, Radiology, Engineering, and Ophthalmology, University of Southern California, Los Angeles, CA 90089, USA
| | - Mary Jo Pugh
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
- Division of Epidemiology, University of Utah, Salt Lake City, UT 84108, USA;
| | - David F. Tate
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
- George E Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA
| | - Frank G. Hillary
- Department of Psychology, Penn State University, State College, PA 16801, USA;
- Department of Neurology, Hershey Medical Center, State College, PA 16801, USA
- Social Life and Engineering Science Imaging Center, Penn State University, State College, PA 16801, USA
| | - Elisabeth A. Wilde
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
- George E Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA
| | - Emily L. Dennis
- Department of Neurology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA; (E.K.); (S.W.L.); (H.M.L.); (S.V.); (M.R.N.); (M.J.P.); (D.F.T.); (E.A.W.)
- George E Wahlen Veterans Affairs Medical Center, Salt Lake City, UT 84148, USA
| |
Collapse
|
39
|
Zygouris NC. Differences in Children and Adolescents with Depression before and after a Remediation Program: An Event-Related Potential Study. Brain Sci 2024; 14:660. [PMID: 39061401 PMCID: PMC11275103 DOI: 10.3390/brainsci14070660] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2024] [Revised: 06/19/2024] [Accepted: 06/26/2024] [Indexed: 07/28/2024] Open
Abstract
Depression is clinically diagnosed when a defined constellation of symptoms manifests over a specific duration with notable severity. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), Major Depressive Disorder (MDD) is characterized by the presence of five or more symptoms persisting for at least two weeks. As a profound mental health condition affecting millions globally, depression presents a considerable challenge for researchers and clinicians alike. In pediatric and adolescent populations, depression can precipitate adverse outcomes, including substance abuse, academic difficulties, risky sexual behaviors, physical health problems, impaired social relationships, and a markedly elevated risk of suicide-up to thirty times higher than the general population. This paper details a study that evaluated the efficacy of Cognitive Behavioral Therapy (CBT) alone vs. CBT combined with selective serotonin reuptake inhibitors (SSRIs) in a treatment program. The study cohort comprised sixteen (16) children and adolescents diagnosed with depression (eight males and eight females) and sixteen (16) typically developing peers (eight males and eight females) aged from 9 to 15 years (Mean age = 11.94, standard deviation = 2.02). Initial assessments employed Event-Related Potentials (ERPs), the Children's Depression Inventory (CDI), and reaction time measurements. The results reveal that participants with depression exhibit cognitive deficits in attention and memory, as evidenced by prolonged P300 latencies. Following intervention with either CBT alone or CBT combined with medication, the depressed participants demonstrated significant improvements, evidenced by lower CDI scores, reduced P300 latencies, and faster reaction times, both compared to their pre-treatment status and relative to the control group.
Collapse
Affiliation(s)
- Nikolaos C Zygouris
- Digital Neuropsychological Assessment Laboratory, Department of Informatics and Telecommunications, University of Thessaly, 35100 Lamia, Greece
| |
Collapse
|
40
|
Bailar-Heath M, Burke R, Thomas D, Morrow CD. A retrospective chart review to assess the impact of alpha-guided transcranial magnetic stimulation on symptoms of PTSD and depression in active-duty special operations service members. Front Psychiatry 2024; 15:1354763. [PMID: 38974919 PMCID: PMC11224515 DOI: 10.3389/fpsyt.2024.1354763] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2023] [Accepted: 05/29/2024] [Indexed: 07/09/2024] Open
Abstract
Introduction Special Operations Forces service members (SOF) are regularly exposed to traumatic and concussive events, increasing the prevalence of symptoms of post-traumatic stress disorder (PTSD) and depression, shortening potential years of service. Methods This retrospective chart review presents preliminary data on a Human Performance Optimization (HPO) program that provided an average of 30 sessions of individualized alpha frequency repetitive transcranial magnetic stimulation (α-rTMS) to active-duty SOF as to reduce symptoms of PTSD and depression following traumatic brain injury. Scores from the PTSD Checklist for DSM-5, PROMIS Depression short form and Perceived Deficits Questionnaire (PDQ) were reviewed. Results Significant reductions were noted after the HPO program in all clinical scales with an average 37% decrease in PCL-5 (p<.01), 11.3% reduction in PROMIS depression T-scores (p<.01), and 45.5% reduction in PDQ scales by session 30 (p<.01), with side effects matching those commonly reported in rTMS. Importantly, the average PCL-5 score decreased from 42.9 to 27 by end of the treatment program, which is below the clinical threshold of 33 for presence of PTSD. For those with depression symptoms scores greater than cut off clinical thresholds at baseline, 46% resolved following treatment. Conclusion This data provides preliminary support for safe application of α-rTMS for symptom reduction in active-duty special operations military personnel.
Collapse
Affiliation(s)
- Marybeth Bailar-Heath
- Human Performance Optimization Department, Brain Health Clinic, Air Force Special Operations Command (AFSOC) Geographically Separated Unit (GSU), Fayetteville, NC, United States
| | | | | | | |
Collapse
|
41
|
Jian YL, Jia S, Shi S, Shi Z, Zhao Y. A nomogram to predict the risk of cognitive impairment in patients with depressive disorder. Res Nurs Health 2024; 47:302-311. [PMID: 38149849 DOI: 10.1002/nur.22364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2023] [Revised: 12/03/2023] [Accepted: 12/13/2023] [Indexed: 12/28/2023]
Abstract
This study was to describe the cognitive function status in patients with depressive disorder and to construct a nomogram model to predict the risk factors of cognitive impairment in these patients. From October 2019 to February 2021, a total of 141 patients with depressive disorder completed the survey in two hospitals. The Montreal cognitive assessment (MoCA) was used with a cutoff score of 26 to differentiate cognitive impairment. Univariable and multivariable logistic regression analyses were conducted to identify independent risk factors. A nomogram was then constructed based on the results of the multivariable logistic regression analysis. The patients had an average MoCA score of 23.99 ± 3.02. The multivariable logistic regression analysis revealed that age (OR: 1.096, 95% CI: 1.042-1.153, p < 0.001), education (OR: 0.065, 95% CI: 0.016-0.263, p < 0.001), depression severity (OR: 1.878, 95% CI: 1.021-3.456, p = 0.043), and sleep quality (OR: 2.454, 95% CI: 1.400-4.301, p = 0.002) were independent risk factors for cognitive impairment in patients with depressive disorder. The area under receiver operating characteristic (ROC) curves was 0.868 (95% CI: 0.807-0.929), indicating good discriminability of the model. The calibration curve of the model and the Hosmer-Lemeshow test (p = 0.571) demonstrated a well-fitted model with high calibration. Age, education, depression severity, and sleep quality were found to be significant predictors of cognitive function. A nomogram model was developed to predict cognitive impairment in patients with depressive disorder, providing a solid foundation for clinical interventions.
Collapse
Affiliation(s)
| | - Shoumei Jia
- School of Nursing, Fudan University, Shanghai, China
| | - Shenxun Shi
- Department of Psychiatry, Fudan University Huashan Hospital, Shanghai, China
| | | | - Ying Zhao
- School of Nursing, Fudan University, Shanghai, China
| |
Collapse
|
42
|
Liao QM, Zhang ZJ, Yang X, Wei JX, Wang M, Dou YK, Du Y, Ma XH. Changes of structural functional connectivity coupling and its correlations with cognitive function in patients with major depressive disorder. J Affect Disord 2024; 351:259-267. [PMID: 38266932 DOI: 10.1016/j.jad.2024.01.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 01/05/2024] [Accepted: 01/17/2024] [Indexed: 01/26/2024]
Abstract
BACKGROUND Previous neuroimaging studies have reported structural and functional brain abnormalities in major depressive disorder (MDD). This study aimed to explore whether the coherence of structural-functional networks was affected by disease and investigate its correlation with clinical manifestations. METHODS The severity of symptoms and cognitive function of 121 MDD patients and 139 healthy controls (HC) were assessed, and imaging data, including diffusion tensor imaging, T1 structural magnetic resonance imaging (MRI) and resting-state functional MRI, were collected. Spearman correlation coefficients of Kullback-Leibler similarity (KLS), fiber number (FN), fractional anisotropy (FA) and functional connectivity (FC) were calculated as coupling coefficients. Double-weight median correlation analysis was conducted to investigate the correlations between differences in brain networks and clinical assessments. RESULTS The percentage of total correct response of delayed matching to sample and the percentage of delayed correct response of pattern recognition memory was lower in MDD. Compared with the HC, KLS-FC coupling between the parietal lobe and subcortical area, FA-FC coupling between the temporal and parietal lobe, and FN-FC coupling in the frontal lobe was lower in MDD. Several correlations between structural-functional connectivity and clinical manifestations were identified. LIMITATIONS First, our study lacks longitudinal follow-up data. Second, the sample size was relatively small. Moreover, we only used the Anatomical Automatic Labeling template to construct the brain network. Finally, the validation of the causal relationship of neuroimaging-behavior factors was still insufficient. CONCLUSIONS The alternation in structural-functional coupling were related to clinical characterization and might be involved in the neuropathology of depression.
Collapse
Affiliation(s)
- Qi-Meng Liao
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China
| | - Zi-Jian Zhang
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China
| | - Xiao Yang
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China
| | - Jin-Xue Wei
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China
| | - Min Wang
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China
| | - Yi-Kai Dou
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China
| | - Yue Du
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China
| | - Xiao-Hong Ma
- Mental Health Center and Psychiatric Laboratory, The State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu, China.
| |
Collapse
|
43
|
Ren FF, Hillman CH, Wang WG, Li RH, Zhou WS, Liang WM, Yang Y, Chen FT, Chang YK. Effects of aerobic exercise on cognitive function in adults with major depressive disorder: A systematic review and meta-analysis. Int J Clin Health Psychol 2024; 24:100447. [PMID: 38371396 PMCID: PMC10869919 DOI: 10.1016/j.ijchp.2024.100447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 01/30/2024] [Indexed: 02/20/2024] Open
Abstract
Background Major Depressive Disorder (MDD) is a highly prevalent psychiatric disorder that impairs the cognitive function of individuals. Aerobic exercise stands out as a promising non-pharmacological intervention for enhancing cognitive function and promoting brain health.While positive impacts of aerobic exercise on executive function in adults with depression have been documented, a comprehensive understanding of its benefits on overall cognitive function, including memory, attention, and processing speed, along with key moderating factors in adults with MDD, remains unexplored. The purpose of the systematic review and meta-analysis was to investigate the effects of aerobic exercise on overall cognitive function in adults with MDD, and to explore whether cognitive sub-domains, aerobic exercise characteristics, and study and sample variables modify the effects of aerobic exercise on cognition. Methods Six English electronic databases (Embase, Cochrane Central, Scopus, APA PsycInfo, PubMed, Web of Science) were searched from inception to 2 April 2023. Randomized trials, including adults aged 18 years or above with a diagnosis of clinical depression, of the effects of aerobic exercise on cognitive function in adults with MDD compared to non-aerobic exercise groups were included. A three-level meta-analysis was conducted utilizing a random-effects model in R. The quality of the studies was evaluated using the Physiotherapy Evidence Database (PEDro) scale. The PROSPERO registration number is CRD42022367350. Results Twelve randomized trials including 945 adults with MDD were included. Results indicated that aerobic exercise significantly improved overall cognitive function (g = 0.21; 95 % confidence intervals [CI] = 0.07, 0.34), and the sub-domains of memory (g = 0.25; 95 % CI = 0.06, 0.44) and executive function (g = 0.12; 95 % CI = 0.04, 0.20). Significant benefits in cognitive function were found from moderate-to-vigorous (mixed) intensity (g = 0.19; 95 % CI = 0.02, 0.37), aerobic exercise conducted 3 times per week (g = 0.23; 95 % CI = 0.10, 0.38), in sessions < 45 min (g = 0.59; 95 % CI = 0.28, 0.90), and 45-60 min (g = 0.16; 95 % CI = 0.07, 0.26), in aerobic exercise intervention ≤ 12 weeks (g = 0. 26; 95 % CI = 0.08, 0.44). Limitations This review only included peer-reviewed English-language studies, which may lead to a language bias. The results of the Egger's test suggested a potential publication bias. Conclusions Aerobic exercise is efficacious in improving overall cognitive function and the sub-domains of memory and executive function in adults with major depressive disorder.
Collapse
Affiliation(s)
- Fei-Fei Ren
- Department of Physical Education, Beijing Language and Culture University, Beijing, China
| | - Charles H. Hillman
- Department of Psychology, Northeastern University, Boston, MA, USA
- Department of Physical Therapy, Movement, and Rehabilitation, Northeastern University, Boston, MA, USA
| | - Wei-Guang Wang
- Department of Physical Education, Beijing Language and Culture University, Beijing, China
| | - Ruei-Hong Li
- Department of Physical Education and Sport Sciences, National Taiwan Normal University, Taipei, Taiwan
| | - Wen-Sheng Zhou
- Department of Physical Education, Jiangsu Second Normal University, Jiangsu, China
| | - Wen-Ming Liang
- Life Sciences Center, Vilnius University, Vilnius, Lithuania
| | - Yong Yang
- Laboratory of Kinesiology and Rehabilitation, School of Physical Education and Sport, Chaohu University, Anhui, China
| | - Feng-Tzu Chen
- Department of Kinesiology, National Tsing Hua University, Hsinchu, Taiwan
| | - Yu-Kai Chang
- Department of Physical Education and Sport Sciences, National Taiwan Normal University, Taipei, Taiwan
- Social Emotional Education and Development Center, National Taiwan Normal University, Taipei, Taiwan
- Institute for Research Excellence in Learning Science, National Taiwan Normal University, Taipei, Taiwan
| |
Collapse
|
44
|
Boesl F, Goereci Y, Schweitzer F, Finke C, Schild AK, Bittner S, Steffen F, Schröder M, Quitschau A, Heine J, Warnke C, Franke C. Cognitive decline in post-COVID-19 syndrome does not correspond with persisting neuronal or astrocytic damage. Sci Rep 2024; 14:5326. [PMID: 38438479 PMCID: PMC10912552 DOI: 10.1038/s41598-024-55881-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2023] [Accepted: 02/27/2024] [Indexed: 03/06/2024] Open
Abstract
Cognitive impairment is the most frequent symptom reported in post-COVID-19 syndrome (PCS). Aetiology of cognitive impairment in PCS is still to be determined. Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are increased in acute COVID-19. Their role as biomarkers in other neurological disorders is under debate. We analysed serum levels of NfL and GFAP as markers for neuronal and astrocytic damage in 53 patients presenting to a PCS Neurology outpatient clinic. Only individuals with self-reported cognitive complaints were included. In these individuals, cognitive complaints were further assessed by comprehensive neuropsychological assessment (NPA). Patients were categorized into subgroups of subjective cognitive decline, single domain impairment, or multi-domain impairment. Serum NfL was in normal range, however an increase of serum GFAP was detected in 4% of patients. Serum NfL and GFAP levels correlated with each other, even when adjusting for patient age (r = 0.347, p = 0.012). NPA showed deficits in 70%; 40% showing impairment in several tested domains. No significant differences were found between serum NfL- and GFAP-levels comparing patients with subjective cognitive decline, single domain impairment, or multi-domain impairment. Persistent neuronal or astrocytic damage did not correlate with cognitive impairment in PCS.
Collapse
Affiliation(s)
- Fabian Boesl
- Department of Neurology, Charité-University Medicine Berlin, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany.
| | - Yasemin Goereci
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Finja Schweitzer
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Carsten Finke
- Department of Neurology, Charité-University Medicine Berlin, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Ann-Katrin Schild
- Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Stefan Bittner
- Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University Mainz, Rhine-Main Neuroscience Network (rmn2), Mainz, Germany
| | - Falk Steffen
- Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunotherapy (FZI), University Medical Center of the Johannes Gutenberg University Mainz, Rhine-Main Neuroscience Network (rmn2), Mainz, Germany
| | - Maria Schröder
- Department of Neurology, Charité-University Medicine Berlin, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Anneke Quitschau
- Department of Neurology, Charité-University Medicine Berlin, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Josephine Heine
- Department of Neurology, Charité-University Medicine Berlin, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany
| | - Clemens Warnke
- Department of Neurology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Christiana Franke
- Department of Neurology, Charité-University Medicine Berlin, Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Hindenburgdamm 30, 12203, Berlin, Germany
| |
Collapse
|
45
|
Fahri Aydın E, Güleç M, Oral E, Gökhan Daloğlu A. The Effects of Fluoxetine and Agomelatine on Neurocognitive Functions and Sleep in Patients with Major Depressive Disorder. PSYCHIAT CLIN PSYCH 2024; 34:9-18. [PMID: 38883888 PMCID: PMC11177640 DOI: 10.5152/pcp.2024.22498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Accepted: 09/21/2023] [Indexed: 06/18/2024] Open
Abstract
Background We aimed to evaluate the effects of 6 weeks of agomelatine versus fluoxetine treatment on cognition and sleep. Methods Agomelatine 25 mg/day and fluoxetine 20 mg/day were administered to major depressive disorder (MDD) patients. Assessments were conducted before the treatment and at the sixth week of treatment via psychometric measures and comprehensive neurocognitive assessments of various functions, including executive skills, attention, memory, verbal fluency, and speed of processing. Results They both improved the evaluated neurocognitive test scores (P < .05), except for the scores of the Digit Span Test (P > .05), but only fluoxetine significantly improved the scores of the Controlled Oral Word Association Test (P = .018). Only in relation to the subjective sleep quality part of the Pittsburgh Sleep Quality Index (P = .035) and the Trail Making Test-B (TMT-B) (P = .046) was there an important difference between the study groups, and agomelatine showed better effects than fluoxetine in these measures. Conclusion Both drugs improved the neurocognitive functioning in the participants. However, the better effect of agomelatine in improving the TMT-B scores suggests that it is a suitable option for MDD patients with noticeable executive disturbances.
Collapse
Affiliation(s)
- Esat Fahri Aydın
- Department of Psychiatry, Atatürk University, Faculty of Medicine, Erzurum, Turkey
| | - Mustafa Güleç
- Department of Psychiatry, Izmir Katip Çelebi University, Atatürk Education and Training Hospital, İzmir, Turkey
| | - Elif Oral
- Department of Psychiatry, Izmir Katip Çelebi University, Atatürk Education and Training Hospital, İzmir, Turkey
| | - Ali Gökhan Daloğlu
- Department of Psychiatry, Mersin City Training and Research Hospital, Mersin, Turkey
| |
Collapse
|
46
|
Little B, Anwyll M, Norsworthy L, Corbett L, Schultz-Froggatt M, Gallagher P. Processing speed and sustained attention in bipolar disorder and major depressive disorder: A systematic review and meta-analysis. Bipolar Disord 2024; 26:109-128. [PMID: 37973384 DOI: 10.1111/bdi.13396] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
Abstract
OBJECTIVES Cognitive impairment is a core feature of bipolar disorder (BD) and major depressive disorder (MDD). Deficits in processing speed (PS) and sustained attention (SA) may be particularly impaired and may underpin a broader profile of deficits, however current knowledge of the nature of these impairments is limited by heterogeneous results in the literature. Few reviews to date have attempted to disentangle sources of heterogeneity to assess the presence and magnitude of impairments in PS and SA in BD and MDD. METHODS One hundred and three studies were reviewed to examine performance in tests of PS and SA in BD (n = 3452) and MDD (n = 5461) compared to healthy controls (n = 8016). Neuropsychological methodology used in the literature was summarised. Data were meta-analysed to assess impairments in PS and SA for each neuropsychological test separately. Subgroup analysis was performed across mood states to investigate sources of heterogeneity. RESULTS Impairments were found across most neuropsychological tests, with small to large effect sizes for BD (range: d = 0.19-0.96) and MDD (range: d = 0.29-0.86). Impairments were present in symptomatic states and euthymia in most cases. Some outcome measures were not impaired in euthymia. Heterogeneity was observed for most neuropsychological tests and remained after separating by mood state. There inadequate data to meta-analyse some outcome measures, particularly for symptomatic groups. CONCLUSION Impairments in PS and SA in BD and MDD can be observed across most neuropsychological tests. Future research should further investigate the nature of these impairments across mood states, controlling for clinical confounds.
Collapse
Affiliation(s)
- Bethany Little
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
- CNNP Lab, Interdisciplinary Computing and Complex BioSystems Group, School of Computing, Newcastle University, Newcastle upon Tyne, UK
| | - Megan Anwyll
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Laura Norsworthy
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Luke Corbett
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Mia Schultz-Froggatt
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| | - Peter Gallagher
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK
| |
Collapse
|
47
|
Minihan S, Kumle L, Maston K, Bal D, Werner‐Seidler A, Christensen H, Schweizer S. The relationship between cognitive and affective control and adolescent mental health. JCPP ADVANCES 2024; 4:e12204. [PMID: 38486950 PMCID: PMC10933673 DOI: 10.1002/jcv2.12204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2023] [Accepted: 10/08/2023] [Indexed: 03/17/2024] Open
Abstract
Background Cognitive control problems have been implicated in the etiology and maintenance of mental health problems, including depression, in adults. Studies in adolescents have been more equivocal, with some showing changes in cognitive control in adolescents with mental health problems, whereas others fail to show an association. This study examines whether adolescent mental health is associated with affective control, the application of cognitive control in affective contexts, which shows more protracted development than cognitive control. Methods The present study investigated the association of cognitive and affective control with depressive symptomatology and self-reported diagnostic history of mental health problems in adolescents. The study included 1929 participants (M age = 13.89) from the Future Proofing Study (N = 6,388, 11-16 years), who completed affective (incl., affective stimuli) and/or cognitive (incl., neutral stimuli) versions of a working memory (backward digit-span) and/or shifting (card-sorting) task at least once within 3 weeks of assessing mental health. Results Poorer working memory was associated with greater depressive symptomatology in adolescents (β = -0.06, p = .004), similarly across cognitive and affective control conditions (β = -0.02, p = .269). Adolescents with self-reported diagnostic history of mental health problems had significantly poorer shifting ability in affective compared to cognitive control conditions (b = 0.05, p = .010), whereas for adolescents with no self-reported diagnoses, shifting ability did not differ between conditions (b = -0.00, p = .649). Conclusions The present analyses suggest that working memory difficulties, in particular, may be associated with the experience of current depressed mood in adolescents. Problems with affective shifting may be implicated in a range of mental health problems in adolescents. Given the ubiquitous need for efficient cognitive functioning in daily life, enhancing cognitive and affective control in adolescents may be a promising means of improving functioning across a range of domains, including affective functioning, and by extension, adolescent mental health.
Collapse
Affiliation(s)
- Savannah Minihan
- School of PsychologyUniversity of New South WalesSydneyNew South WalesAustralia
| | - Levi Kumle
- Department of Experimental PsychologyUniversity of OxfordOxfordUK
| | - Kate Maston
- Black Dog InstituteUniversity of New South WalesSydneyNew South WalesAustralia
- Discipline of Psychiatry and Mental HealthUniversity of New South WalesSydneyNew South WalesAustralia
| | - Debopriyo Bal
- Black Dog InstituteUniversity of New South WalesSydneyNew South WalesAustralia
| | - Aliza Werner‐Seidler
- School of PsychologyUniversity of New South WalesSydneyNew South WalesAustralia
- Black Dog InstituteUniversity of New South WalesSydneyNew South WalesAustralia
| | - Helen Christensen
- Black Dog InstituteUniversity of New South WalesSydneyNew South WalesAustralia
- Discipline of Psychiatry and Mental HealthUniversity of New South WalesSydneyNew South WalesAustralia
| | - Susanne Schweizer
- School of PsychologyUniversity of New South WalesSydneyNew South WalesAustralia
- Department of PsychologyUniversity of CambridgeCambridgeUK
| |
Collapse
|
48
|
Lai H, Treisman G, Celentano DD, Gerstenblith G, Mandler RN, Khalsa J, Charurat M, Lai S, Pearson G. Elevated homocysteine levels may moderate and mediate the association between HIV and cognitive impairment among middle-aged and older adults in an underserved population in Baltimore, Maryland. Int J STD AIDS 2024; 35:296-307. [PMID: 38065684 DOI: 10.1177/09564624231218762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/02/2024]
Abstract
Background: In the antiretroviral therapy (ART) era, HIV-associated neurocognitive disorders (HAND) remain a considerable challenge for people with HIV, yet not all such disorders can be attributed to HIV alone. This study aimed to: (1) identify factors influencing neurocognitive impairment (NCI) utilizing the NIH Toolbox Cognition Battery (NIHTB-CB) as per the revised research criteria for HAND; (2) ascertain the moderating role of high homocysteine levels in the association between NCI and HIV; and (3) assess the mediating effect of elevated homocysteine levels on this association.Methods: We analyzed data from 788 adults (≥45 years) participating in a study on HIV-related comorbidities in underserved Baltimore communities, using NIHTB-CB to gauge neurocognitive performance. Special attention was given to results from the Dimensional Change Card Sort (DCCS) test within the executive function domain during causal mediation analysis.Results: Overall, HIV was not associated with NCI presence. However, HIV was associated with NCI among individuals with homocysteine >14 μmol/L. Furthermore, HIV was both directly and indirectly associated with NCI in DCCS test scores. Notably, the mediating role of elevated homocysteine in DCCS scores was only observable among individuals who had never used cocaine or had used it for ≤ 10 years, suggesting that extended cocaine use may have a substantial influence on cognitive performance.Conclusions: The findings from this study suggest elevated homocysteine levels may moderate and mediate the association between HIV and neurocognitive impairment.
Collapse
Affiliation(s)
- Hong Lai
- Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Glenn Treisman
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - David D Celentano
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Gary Gerstenblith
- Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - Raul N Mandler
- National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, USA
| | - Jag Khalsa
- Department of Microbiology, Immunology and Tropical Diseases, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Man Charurat
- Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Shenghan Lai
- Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Godfrey Pearson
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| |
Collapse
|
49
|
Zang JCS, Hohoff C, Van Assche E, Lange P, Kraft M, Sandmann S, Varghese J, Jörgens S, Knight MJ, Baune BT. Immune gene co-expression signatures implicated in occurence and persistence of cognitive dysfunction in depression. Prog Neuropsychopharmacol Biol Psychiatry 2023; 127:110826. [PMID: 37451594 DOI: 10.1016/j.pnpbp.2023.110826] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/30/2023] [Revised: 06/29/2023] [Accepted: 07/09/2023] [Indexed: 07/18/2023]
Abstract
Cognitive dysfunction contributes significantly to the burden caused by Major Depressive Disorder (MDD). Yet, while compelling evidence suggests that different biological processes play a part in both MDD aetiology and the development of cognitive decline more generally, we only begin to understand the molecular underpinnings of depression-related cognitive impairment. Developments in psychometric assessments, molecular high-throughput methods and systems biology derived analysis strategies advance this endeavour. Here, we aim to identify gene expression signatures associated with cognitive dysfunction and cognitive improvement following therapy using RNA sequencing to analyze the whole blood-derived transcriptome of altogether 101 MDD patients who enrolled in the CERT-D study. The mRNA(Nova)Seq based transcriptome was analyzed from whole blood taken at baseline assessment, and patients' cognitive performance was measured twice at baseline and following eight weeks of therapy by means of the THINC integrated tool. Thirty-six patients showed comparatively low cognitive performance at baseline assessment, and 32 patients showed comparatively strong cognitive improvement following therapy. Differential gene expression analysis was performed using limma to a significance threshold of 0.05 and a logFC cutoff of |1.2|. Although we observed some indications for expression differences related to low cognitive performance and cognitive therapy response, signals did not withstand adjustment for multiple testing. Applying WGCNA, we retrieved altogether 25 modules of co-expressed genes and we used a combination of correlational and linear analyses to identify modules related to baseline cognitive performance and cognitive improvement following therapy. Three immune modules reflected distinct but interrelated immune processes (the yellow module: neutrophil-mediated immunity, the darkorange module: interferon signaling, the tan module: platelet activation), and higher expression of the yellow (r = -0.21, p < .05), the dark orange (r = 0.2, p < .05), and the tan (r = -0.23, p < .05) module correlated significantly negatively with patients' cognitive baseline performance. Patients' cognitive baseline performance was a significant predictor of the darkorange module (b = -0.039, p < .05) and the tan module's expression (b = 0.02, p < .05) and was close to becoming a significant predictor of the yellow module's expression (b = -0.02, p = .05). Furthermore, patients characterized by comparatively low cognitive performance at baseline showed significantly higher expression of the tan module when compared to all other patients F(1,97) = 4.32, p < .05, η= 0.04. Following eight weeks of treatment, we observed altogether significant improvement in patients' cognitive performance (b = 0.30, p < .001), and patients with comparatively high cognitive gain showed noticeably lower, but not significantly lower F(1,98) = 3.76, p = .058, expression of a dark turquoise module, which reflects complement and B-cell-associated immune processes. Noteworthy, the relation between cognitive performance and module expression remained observable after controlling for symptom severity and BMI, which partly accounted for variance in module expression. As such, our findings provide further evidence for the involvement of immune processes in MDD related cognitive dysfunction and they suggest that different immune processes contribute to the development and long-term persistence of cognitive dysfunction in the context of depression.
Collapse
Affiliation(s)
- Johannes C S Zang
- Department of Psychiatry, University of Münster, 48149 Münster, Germany.
| | - Christa Hohoff
- Department of Psychiatry, University of Münster, 48149 Münster, Germany.
| | - Evelien Van Assche
- Department of Psychiatry, University of Münster, 48149 Münster, Germany.
| | - Pia Lange
- Institute of Medical Informatics, University of Münster, Münster, Germany.
| | - Manuel Kraft
- Department of Psychiatry, University of Münster, 48149 Münster, Germany.
| | - Sarah Sandmann
- Institute of Medical Informatics, University of Münster, Münster, Germany.
| | - Julian Varghese
- Institute of Medical Informatics, University of Münster, Münster, Germany.
| | - Silke Jörgens
- Department of Psychiatry, University of Münster, 48149 Münster, Germany.
| | - Matthew J Knight
- Discipline of Psychiatry, Adelaide Medical School, University of Adelaide, Adelaide, Australia
| | - Bernhard T Baune
- Department of Psychiatry, University of Münster, 48149 Münster, Germany; Department of Psychiatry, Melbourne Medical School, The University of Melbourne, Parkville, VIC 3010, Australia; The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3010, Australia.
| |
Collapse
|
50
|
Samaryn E, Galińska-Skok B, Nobis A, Zalewski D, Maciejczyk M, Gudowska-Sawczuk M, Mroczko B, Zalewska A, Waszkiewicz N. The Effect of Antidepressant Treatment on Neurocognitive Functions, Redox and Inflammatory Parameters in the Context of COVID-19. J Clin Med 2023; 12:7049. [PMID: 38002663 PMCID: PMC10671940 DOI: 10.3390/jcm12227049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Revised: 11/08/2023] [Accepted: 11/09/2023] [Indexed: 11/26/2023] Open
Abstract
Inflammation is an important component of the etiopathology of depression that uses oxidative and nitrosative stress (O&NS) and elevated inflammatory markers. SARS-CoV-2 infection is also associated with abnormal inflammatory processes, which may impair effective treatment of depression in COVID-19 survivors. In the presented study, thirty-three hospitalized patients with major depressive disorder (MDD) were started on antidepressant treatment, and twenty-one were re-evaluated after 4-6 weeks. The control group consisted of thirty healthy volunteers. All participants underwent neuropsychiatric evaluation, biochemical blood and urine analyses. The results of the research demonstrated positive correlations of the Hamilton Depression Rating Scale (HAM-D) scores with serum catalase (CAT) and urinary S-Nitrosothiols levels, and the Beck Depression Inventory (BDI) scores with serum reduced glutathione (GSH) and superoxide dismutase (SOD) levels. Depressed patients with a history of COVID-19 prior to the treatment had higher urinary nitric oxide (NO) levels and lower serum glutathione peroxidase (GPx) levels. In the control group, COVID-19 survivors had higher levels of urinary N-formylkynurenine (NFK). Our results suggest that the antidepressant treatment has a modulating effect on O&NS, reduces depressive symptoms and improves cognitive functions The present study does not indicate that clinical response to antidepressant treatment is associated with COVID-19 history and baseline SARS-CoV-2 antibody levels. Nevertheless, further research in this area is needed to systematize antidepressant treatment in COVID-19 survivors.
Collapse
Affiliation(s)
- Eliza Samaryn
- Department of Psychiatry, Medical University of Bialystok, 15-272 Bialystok, Poland (D.Z.)
| | - Beata Galińska-Skok
- Department of Psychiatry, Medical University of Bialystok, 15-272 Bialystok, Poland (D.Z.)
| | - Aleksander Nobis
- Department of Psychiatry, Medical University of Bialystok, 15-272 Bialystok, Poland (D.Z.)
| | - Daniel Zalewski
- Department of Psychiatry, Medical University of Bialystok, 15-272 Bialystok, Poland (D.Z.)
| | - Mateusz Maciejczyk
- Department of Hygiene, Epidemiology, and Ergonomics, Medical University of Bialystok, 15-022 Bialystok, Poland
| | - Monika Gudowska-Sawczuk
- Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
| | - Barbara Mroczko
- Department of Biochemical Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
- Department of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland
| | - Anna Zalewska
- Department of Restorative Dentistry, Medical University of Bialystok, 15-276 Bialystok, Poland
| | - Napoleon Waszkiewicz
- Department of Psychiatry, Medical University of Bialystok, 15-272 Bialystok, Poland (D.Z.)
| |
Collapse
|